Patent Grant
12048643
A person or animal may have limited or impaired mobility so typical urination processes are challenging or impossible. For example, a person may experience or have a disability that impairs mobility. A person may have restricted travel conditions such as those experienced by pilots, drivers, and workers in hazardous areas. Additionally, sometimes bodily fluids collection is needed for monitoring purposes or clinical testing.
Urinary catheters, such as a Foley catheter, can address some of these circumstances, such as incontinence. Unfortunately, urinary catheters can be uncomfortable, painful, and can lead to complications, such as infections. Additionally, bed pans, which are receptacles used for the toileting of bedridden patients are sometimes used. However, bedpans can be prone to discomfort, spills, and other hygiene issues.
Embodiments disclosed herein are directed to fluid collection assemblies that include at least one inflation device, methods for using the same, and systems including the same. In an embodiment, a fluid collection assembly is disclosed. The fluid collection assembly includes a fluid impermeable barrier defining a chamber, at least one opening, and at least one fluid outlet. The fluid collection assembly also includes at least one porous material disposed in the chamber. The fluid collection assembly further includes at least one inflation device including at least one bladder and at least one valve. The at least one bladder includes one or more walls defining an interior region. The at least one valve is configured to selectively permit at least one inflation fluid to flow into and out of the interior region to switch the at least one bladder between a first state and a second state. An amount of the at least one inflation fluid present in the interior region is greater when the at least one bladder is in the second state than when the at least one bladder is in the first state.
In an embodiment, a system is disclosed. The system includes a fluid collection assembly, a fluid storage container, a vacuum source, and one or more conduits. The one or more conduits operably couple at least one fluid outlet of the fluid collection assembly, the fluid storage container, and the vacuum source together. The fluid collection assembly of the system includes any one of the fluid collection assemblies disclosed herein.
In an embodiment, a method of using a fluid collection assembly is disclosed. The method includes positioning at least one opening of the fluid collection assembly adjacent to a female urethra or to receive a male penis therethrough. The fluid collection assembly includes a fluid impermeable barrier defining the at least one opening, a chamber, and the at least one fluid outlet. The fluid collection assembly also includes at least one porous material disposed in the chamber. The fluid collection assembly further includes at least one inflation device including at least one bladder and at least one valve, the at least one bladder including one or more walls defining an interior region. The method includes flowing at least one inflation fluid through the at least one valve and into the interior region of the at least one inflation element.
Features from any of the disclosed embodiments may be used in combination with one another, without limitation. In addition, other features and advantages of the present disclosure will become apparent to those of ordinary skill in the art through consideration of the following detailed description and the accompanying drawings.
The drawings illustrate several embodiments of the present disclosure, wherein identical reference numerals refer to identical or similar elements or features in different views or embodiments shown in the drawings.
Embodiments disclosed herein are directed to fluid collection assemblies that include at least one inflation device, methods for using the same, and systems including the same. An example fluid collection assembly includes a fluid impermeable barrier defining at least one opening, a chamber, and at least one fluid outlet. The fluid collection assembly also includes at least one porous material disposed in the chamber. As previously discussed, the fluid collection assembly further includes at least one inflation device. The inflation device includes at least one bladder having one or more walls defining an interior region. The inflation device also includes at least one valve configured to selectively permit fluid flow into and out of the interior region to switch the at least one bladder between a first state (e.g., a deflated and/or initial state) and a second state (e.g., an at least partially inflated state). The inflation device may facilitate securement of the fluid collection assembly with certain patients (e.g., underweight patients or patients with thin thighs) when the bladder of the inflation device is in the second state.
The fluid collection assembly is configured to be positioned about or around the pubic region of a patient. When the patient is a female, the pubic region may include the vulva (e.g., labia majora, labia minora, clitoris, urethral opening, etc.), mons pubis, the perineum, buttocks, and the inner thighs of the patient. When the patient is a male, the pubic region may include the penis, the testicles, the mons pubis, the buttocks, and the inner thighs of the patient.
The fluid collection assembly may be flexible thereby allowing the fluid collection assembly to conform to the size and topography of the pubic region since the size and topography of the pubic region may vary significantly from person to person. Conforming the fluid collection assembly to the pubic region may prevent or inhibit embarrassing and unsanitary leaks of bodily fluids (e.g., urine, blood, sweat, etc.). In some embodiments, the fluid collection assembly may rely on contact pressure from the thighs of the individual to remain conformed to the pubic region. However, it has been found that the thighs of some individuals may not provide sufficient contact pressure to allow the fluid collection assembly to remain conformed to the pubic when the fluid collection assembly is in the first (e.g., deflated) state. For instance, it has been found that underweight patients and other patients having thin thighs may not provide sufficient contact pressure to the fluid collection assembly to allow the fluid collection assembly to remain conformed to the pubic region when the fluid collection assembly is in the first state. Some conventional fluid collection assemblies that do not include the inflation device may have similar problems remaining conformed to the pubic region.
The inflatable devices disclosed herein allow the fluid collection assemblies disclosed herein to remain conformed to the pubic region even when the patient is underweight or has thin thighs. For example, when the fluid collection assembly does not have sufficient contact pressure from the thighs to remain conformed to the pubic region, at least one inflation fluid (e.g., gas or liquid) may be added to the interior region of the bladder through the valve. Adding the fluid to the interior region switches the bladder from the first state to the second state. Changing the bladder from the first state to the second shape also changes the shape and/or size of the fluid collection assembly. The changes in the shape and/or size of the fluid collection assembly may allow the fluid collection assembly to press against the thighs so the thighs provide sufficient contact pressure to allow the fluid collection assembly to remain conformed to the female anatomy.
The fluid collection assembly is configured to be disposed against the patient so the opening of the fluid impermeable barrier is disposed adjacent to at least the urethral opening of the patient. After positioning the fluid collection assembly, the patient may discharge bodily fluids, either controllably or uncontrollably. The porous material may remove the bodily fluids from the patient and move the bodily fluids through the opening and the chamber to the fluid outlet. The bodily fluids may be removed from the chamber via the fluid outlet by using at least one gravity (e.g., the fluid outlet is at the gravimetric low point of the chamber) or a suction force provided by a vacuum which suctions the bodily fluids from the chamber.
The inflation device 112 includes a bladder 114. The bladder 114 includes one or more walls 116 defining an interior region 118. The inflation device 112 also includes at least one valve 120 in fluid communication with the interior region 118. The valve 120 is configured to selectively permit flow of an inflation fluid into and/or out the interior region 118. For example, the valve 120 may allow an inflation fluid to enter the interior region 118 when it is desirable to at least one of increase the size or change the shape of the bladder 114 which, in turn, at least one of increases the size or changes the shape of the fluid collection assembly 100. The valve 120 may also enable removing the inflation fluid from the interior region 118 when it is desirable to at least one of decrease the size or change the shape (e.g., return to the initial shape) of the bladder 114 which, in turn, at least one of decreases the size or changes the shape of the fluid collection assembly 100.
Disposing or removing the inflation fluids into and from the inflation region 118 changes the state of the bladder 114. The bladder 114 may exhibit at least a first state and a second state. The amount (volume or weight) of inflation fluids present in the inflation region 118 is greater when the bladder 114 is in the second state than when the bladder 114 is in the first state. In an example, as shown in
The bladder 114 may exhibit one or more additional states (e.g., third state, fourth state, and so forth) besides the first and second states discussed above. In an embodiment, the one or more additional states may include less inflation fluids in the inflation region 118 (e.g., is more deflated) than the first state (e.g., the first state is a partially inflated state). In such an embodiment, the one or more additional states may include a deflated or partially deflated state and may be formed by removing inflation fluids from the inflation region 118 when the bladder 114 is in the first or second state. In an embodiment, the one or more additional states may include more inflation fluids in the inflation region 118 (e.g., is more inflated) than the first state (e.g., the first state is a deflated or partially inflated state) and include less inflation fluids in the inflation region 118 than the second state. In such an embodiment, the one or more additional states include a partially inflated state and may be formed by adding or removing inflation fluids to the inflation region 118 when the bladder 114 is in the first state or second state, respectively. In an embodiment, the one or more additional states may include more inflation fluids in the inflation region 118 than the second state (e.g., the second state is a partially inflated state). In such an embodiment, the one or more additional states may be an at least partially inflated state and may be formed by adding inflation fluids to the inflation region 118 when the bladder 114 is in the first state or second state. It is noted that, in some embodiments, the bladder 114 may only include the first and second states.
As shown in
The walls 116 are formed from a material is substantially impermeable to the inflation fluid (e.g., substantially impermeable to a gas and/or a liquid) which allows the bladder 114 to retain the inflation fluids without embarrassing leaks. The walls 116 may also be formed from a flexible material. The flexible material of the walls 116 allows the bladder 114 and, by extension, the fluid collection assembly 100 to at least one of increase in size or change a shape thereof. For example, the flexible material of the walls 116 allow the interior region 118 to increase a volume thereof when the interior region 118 receives an inflation fluid and decrease a volume thereof when inflation fluids are removed from the interior region 118. Examples of materials that may form the walls 116 of the bladder 114 include silicone, rubber, latex, polychloroprene, nylon fabric, polypropylene, polyvinyl chloride, nitrile rubber, other suitable polymers, a metal foil, a composite, or combinations thereof. It is noted that the walls 116 do not contact the patient in the illustrated embodiment and might be formed from a biocompatible material. In an embodiment, the walls 116 are configured to stretch (e.g., elastically or plastically stretch) so the walls 116 remain taut when the bladder 114 is at least partially inflated. In an embodiment, the wall 116 forms a plurality of wrinkles when the bladder 114 is at least partially deflated and adding inflation fluid into the inflation region 118 decreases the wrinkles, similar to an accordion.
The valve 120 may include any suitable valve configured to allow for the controllable addition and remove of inflation fluids from the inflation region 118. In an embodiment, the valve 120 is a luer valve and includes a male-tapper fitting or a female-taper fitting. In an embodiment, the valve 120 includes a fluid impermeable membrane with a slit or opening formed. The slit or opening of the fluid impermeable membrane remains substantially closed when no external load is applied thereto but opens when an external load is applied thereto (e.g., an external load caused by pressing a syringe against the fluid impermeable membrane). In an embodiment, the valve 120 may include a mechanical valve, such as a ball valve, a butterfly valve, or any other suitable mechanical valve. The mechanical valve may be manually operated or controlled using a computer. In an embodiment, the valve 120 may include a check valve to limit leaks from the bladder 114 and to make the fluid collection assembly 100 easier to use. In such an embodiment, the valve 120 may only add or remove (but not both) inflation fluid from the inflation region 118 and, as such, the fluid collection assembly 100 is configured for single use.
In an embodiment, as illustrated, the valve 120 may extend outwardly from the bladder 114. For example, the valve 120 may extend from the bladder 114, through a portion of the porous material 110, and through the fluid impermeable barrier 102 thereby allowing a user (e.g., medical practitioner or patient) of the fluid collection assembly 100 easily access to the valve 120. As shown, the valve 120 may extend a short distance only from the fluid impermeable barrier 102, such as about 2 cm or less, about 1.5 cm or less, about 1 cm or less, about 0.75 cm or less, about 0.5 cm or less, about 0.25 cm or less, or in ranges of about 0.25 cm to about 0.75 cm, about 0.5 cm to about 1 cm, about 0.75 cm to about 1.5 cm, or about 1 cm to about 2 cm. However, the valve 120 may extend a significant distance from the fluid impermeable barrier 102, such as a distance that is about 2 cm or greater, about 5 cm or greater, about 10 cm or greater, about 50 cm or greater, about 100 cm or greater, about 500 cm or greater, about 1 m or greater, about 2 m or greater, or in ranges of about 2 cm to about 10 cm, about 5 cm to about 50 cm, about 10 cm to about 100 cm, about 50 cm to about 500 cm, about 100 cm to about 1 m, or about 500 cm to about 2 m. When the valve 120 extends a significant distance from the fluid impermeable barrier 102, the valve 120 may include a flexible tube which allows a user of the fluid collection assembly 100 to easily access to the valve 120 while the fluid collection assembly 100 is positioned adjacent to the pubic region without having the user near the pubic region (which the patient may find uncomfortable).
In an embodiment, as illustrated, the valve 120 extends from or near a back surface 122 of the fluid impermeable barrier 102. The back surface 122 of the fluid impermeable barrier 102 is the surface of the fluid impermeable barrier 102 opposite the opening 104. The valve 120 at or near the back surface 122 may allow a user of the fluid collection assembly 100 to access the valve 120 when the fluid collection assembly 100 is adjacent to the pubic region since, generally, the pubic region and the inner thighs of the patient may contact or obstruct the surfaces of the fluid impermeable barrier 102 except the back surface 122. Further, the valve 120 at or near the back surface 122 prevents the valve 120 from pressing against the pubic region and the inner thighs during use which may cause discomfort.
In an embodiment, the fluid collection assembly 100 may only include a single bladder 114 and/or a single valve 120. In an embodiment, the fluid collection assembly 100 may include a plurality of bladders 114 and/or a plurality of valves 120. For example, as illustrated, the fluid collection assembly 100 may include two bladders 114 on each lateral side of the fluid collection assembly 100 which allows the fluid collection assembly 100 to increase is size laterally which allows the fluid collection assembly 100 to contact the thighs of the patient. Each bladder 114 may include one or more valves 120 to allow for independent inflation of the bladders 114 which allows for better control of the shape and size of the fluid collection assembly 100. However, the fluid collection assembly 100 may only include a single valve 120 for two or more bladders 114. In some examples, a single bladder 114 may include a plurality of valves 120, for instance, to increase the likelihood that one valve 120 is easily accessible.
The inflation device 112 may include additional components other than the components discussed above. For example, the inflation device 112 may include less flexible material (e.g., rigid material or material that is less flexible than the walls 116) that are used to control the shape of the bladder 114 when the bladder 114 is inflated (e.g., switched from the first state to the second state). The less flexible material may form parts of the walls 116, wrap around the walls 116, or extend in the inflation region 118 between opposing portions of the walls 116 which limits expansion of the walls 116 at and near the less flexible material.
The at least one inflation fluid added or removed from the interior region 118 may include any suitable fluid, such as any suitable liquid or any suitable gas. In an embodiment, the inflation fluids are formed from a generally regarded as safe (“GRAS”) material. Forming the inflation fluids from a GRAS materials may decrease health risks caused by inadvertently exposing the patient to the inflation fluids. Examples of GRAS materials that may form the inflation fluids includes water, saline solution, alcohol solution, atmospheric air, nitrogen, any other GRAS material, or combinations thereof.
As previously discussed, the fluid collection assembly 100 includes a fluid impermeable barrier 102. In the illustrated embodiment, the fluid impermeable barrier 102 is distinct from the inflation device 112 and is spaced from the inflation device 112 by at least a portion of the porous material 110.
The fluid impermeable barrier 102 may be formed of any suitable fluid imporous material(s), such as a fluid impermeable polymer (e.g., silicone, polypropylene, polyethylene, polyethylene terephthalate, a polycarbonate, etc.), a metal film, natural rubber, another suitable material, or combinations thereof. The fluid impermeable barrier 102 substantially prevents the bodily fluids from passing through the fluid impermeable barrier 102. In an example, the fluid impermeable barrier 102 may be air permeable and fluid impermeable. In such an example, the fluid impermeable barrier 102 may be formed of a hydrophobic material that defines a plurality of pores. At least a surface of the fluid impermeable barrier 102 that may contact the patient may be formed from a soft and/or smooth material (e.g., silicone), thereby reducing chaffing. In an embodiment, the fluid impermeable barrier 102 may be formed from a flexible material, such as silicone, which allows the fluid impermeable barrier 102 to be bent into a shape that conforms the anatomy of the individual. Further, as shown in
The fluid impermeable barrier 102 may define a hole that allows the valve 120 to extend through the fluid impermeable barrier 102. For example, the fluid impermeable barrier 102 may define the hole at or near the back surface 122 thereof. The hole formed in the fluid impermeable barrier 102 is configured to form a substantially fluid tight seal against the valve 120 or a sealant is applied between the fluid impermeable barrier 102 and the valve 120 to prevent bodily fluids from leaking through the hole.
In some examples, the fluid impermeable barrier 102 may be tubular (ignoring the opening), such as substantially cylindrical (as shown), oblong, prismatic, or flattened tubes when the bladder 114 is in the first state and/or the second state. During use, the outer surface 124 of the fluid impermeable barrier 102 may contact the patient. The fluid impermeable barrier 102 may be sized and shaped to fit in the gluteal cleft between the legs of a female user when the bladder 114 are in at least the second state.
The opening 104 provides an ingress route for fluids to enter the chamber 106. The opening 104 may be defined by the fluid impermeable barrier 102 such as by an inner edge of the fluid impermeable barrier 102. For example, the opening 104 is formed in and extends through the fluid impermeable barrier 102, from the outer surface 124 to the inner surface 126, thereby enabling fluid(s) to enter the chamber 106 from outside of the fluid collection assembly 100. The opening 104 may be an elongated hole in the fluid impermeable barrier 102. For example, the opening 104 may be defined as a cut-out in the fluid impermeable barrier 102. The opening 104 may be located and shaped to be positioned adjacent to a female urethra.
The fluid collection assembly 100 may be positioned proximate to the female urethral opening and urine may enter the chamber of the fluid collection assembly 100 via the opening 104. The fluid collection assembly 100 is configured to receive the fluid(s) into the chamber 106 via the opening 104. When in use, the opening 104 may have an elongated shape that extends from a first location below the urethral opening (e.g., at or near the anus or the vaginal opening) to a second location above the urethral opening (e.g., at or near the top of the vaginal opening or the pubic hair).
The opening 104 may have an elongated shape because the space between the legs of a female is relatively small when the legs of the female are closed, thereby only permitting the flow of the fluid(s) along a path that corresponds to the elongated shape of the opening 104 (e.g., longitudinally extending opening). The opening 104 in the fluid impermeable barrier 102 may exhibit a length measured along the longitudinal axis of the fluid collection assembly 100 that may be at least about 10% of the length of the fluid collection assembly 100, such as about 25% to about 50%, about 40% to about 60%, about 50% to about 75%, about 65% to about 85%, or about 75% to about 95% of the length of the fluid collection assembly 100.
The opening 104 in the fluid impermeable barrier 102 may exhibit a width measured transverse to the longitudinal axis of the fluid collection assembly 100 that may be, when the fluid collection assembly 100 and the bladder 114 are in the first state, at least about 10% of the circumference of the fluid collection assembly 100, such as about 25% to about 50%, about 40% to about 60%, about 50% to about 75%, about 65% to about 85%, or about 75% to about 100% of the circumference of the fluid collection assembly 100. The opening 104 may exhibit a width that is greater than 50% of the circumference of the fluid collection assembly 100 since the vacuum (e.g., suction) through the conduit 128 pulls the fluid through the porous material 110 and into the conduit 128. As shown in
In some examples, the opening 104 may be vertically oriented (e.g., having a major axis parallel to the longitudinal axis of the fluid collection assembly 100). In some examples (not shown), the opening 104 may be horizontally oriented (e.g., having a major axis perpendicular to the longitudinal axis of the fluid collection assembly 100). In an example, the fluid impermeable barrier 102 may be configured to be attached to the individual, such as adhesively attached (e.g., with a hydrogel adhesive) to the individual. According to an example, a suitable adhesive is a hydrogel layer.
As previously discussed, the fluid impermeable barrier 102 may define fluid outlet 108 configured to remove bodily fluids from the chamber 106. The fluid outlet 108 is distinct from the opening 104 and the valve 120. In some examples, the fluid outlet 108 is sized to receive the conduit 128. The conduit 128 may be disposed in the chamber 106 via the fluid outlet 108. The fluid outlet 108 may be sized and shaped to form an at least substantially fluid tight seal against the conduit 128 or the at least one tube substantially preventing the bodily fluids from escaping the chamber 106.
The fluid impermeable barrier 102 may include markings thereon, such as one or more markings to aid a user in aligning the fluid collection assembly 100 on the patient. For example, a line on the fluid impermeable barrier 102 (e.g., opposite the opening 104) may allow a healthcare professional to align the opening 104 over the urethral opening of the patient. In examples, the markings may include one or more of alignment guide or an orientation indicator, such as a stripe or hashes. Such markings may be positioned to align the fluid collection assembly 100 to one or more anatomical features such as a pubic bone, etc.
As previously discussed, the fluid collection assembly 100 includes porous material 110 disposed in the chamber 106. The porous material 110 may cover at least a portion (e.g., all) of the opening 104. The porous material 110 is exposed to the environment outside of the chamber 106 through the opening 104. The permeable properties referred to herein may be wicking, capillary action, absorption, diffusion, or other similar properties or processes, and are referred to herein as “permeable” and/or “porous.” The porous material 110 may also wick the bodily fluids generally towards an interior of the chamber 106, as discussed in more detail below. The porous material 110 may include one or more of a fluid permeable membrane 130 or a fluid permeable support 132.
In an embodiment, at least a portion of the porous material 110 may be a wicking material configured to wick and/or allow transport of the bodily fluids away from the opening 104, thereby preventing bodily fluids from escaping the chamber 106. The porous material 110 may not include absorption of the bodily fluids into the w porous material 110. Put another way, substantially no absorption of the bodily fluids into the porous material 110 may take place after the wicking material is exposed to the bodily fluids. While no absorption is desired, the term “substantially no absorption” may allow for nominal amounts of absorption of the bodily fluids into the wicking material (e.g., absorbency), such as about 30 wt % or less of the dry weight of the wicking material, about 20 wt % or less, 10 wt % or less, about 7 wt % or less, about 5 wt % or less, about 3 wt % or less, about 2 wt % or less, about 1 wt % or less, or about 0.5 wt % or less of the dry weight of the wicking material.
The fluid collection assembly 100 may include the fluid permeable membrane 130 disposed in the chamber 106. The fluid permeable membrane 130 may cover at least a portion (e.g., all) of the opening 104. The fluid permeable membrane 130 may be composed to pull/push the bodily fluids away from the opening 104, thereby promoting fluid flow into the chamber 106, prevent fluid remaining on the vulva of the patient, and preventing the bodily fluids from escaping the chamber 106.
The fluid permeable membrane 130 may include any material that may be permeable to the bodily fluids. For example, the fluid permeable membrane 130 may include fabric, such as a gauze (e.g., a silk, linen, or cotton gauze), another soft fabric, or another smooth fabric. Forming the fluid permeable membrane 130 from gauze, soft fabric, and/or smooth fabric may reduce chaffing caused by the fluid collection assembly 100 and makes wearing the fluid collection assembly more comfortable. In an embodiment, the fluid permeable membrane 130 is formed from a flexible material, such as gauze, since the shape and/or size of the fluid permeable membrane 130 may change when the fluid collection assembly 100 and the bladder 114 switch between states, as shown in
The fluid collection assembly 100 may include the fluid permeable support 132 disposed in the chamber 106. The fluid permeable support 132 is configured to support the fluid permeable membrane 130 and maintain the shape of the chamber 106 since the fluid impermeable barrier 102 and the fluid permeable membrane 130 may be formed from a relatively foldable, flimsy, or otherwise easily deformable material. For example, the fluid permeable support 132 may be positioned so the fluid permeable membrane 130 is disposed between the fluid permeable support 132 and the fluid impermeable barrier 102. The fluid permeable support 132 may support and maintain the position of the fluid permeable membrane 130 and the shape of the chamber 106. The fluid permeable support 132 may include any material that may be permeable to the bodily fluids, such as any of the fluid permeable membrane 130 materials disclosed above. For example, the fluid permeable membrane 130 material(s) may be utilized in a more dense or rigid form than in the fluid permeable membrane 130 when used as the fluid permeable support 132. The fluid permeable support 132 may be formed from any fluid porous material that is less deformable than the fluid permeable membrane 130. For example, the fluid permeable support 132 may include a porous polymer (e.g., nylon, polyester, polyurethane, polyethylene, polypropylene, etc.) structure (e.g., spun fibers such as spun nylon fibers), nonwoven material, or a foam (e.g., an open cell foam). In some examples, the fluid permeable support 132 may be formed from a natural material, such as cotton, wool, silk, or combinations thereof. In such examples, the material may have a coating to prevent or limit absorption of the bodily fluids into the material, such as a water repellent coating. In some examples, the fluid permeable support 132 may be formed from fabric, felt, gauze, or combinations thereof.
In an embodiment, as illustrated, the bladder 114 is positioned between the fluid permeable membrane 130 and the fluid permeable support 132 (e.g., the bladder 114 is positioned in the chamber 106). The bladder 114 may be positioned between the fluid permeable membrane 130 and the fluid permeable support 132 since that at least some materials that form the fluid impermeable barrier 102 and the fluid permeable membrane 130 exhibit a flexibility that allows the fluid impermeable barrier 102 and the fluid permeable membrane 130 to accommodate the size and/or shape changes discussed above. The fluid permeable membrane 130 also covers the bladder 114 thereby protecting the bladder 114 from objects that may puncture the bladder 114. The fluid impermeable barrier 102 may also cover at least a portion of the bladder 114 thereby also protecting the bladder 114 from objects. The bladder 114 may be positioned in the chamber 106 so the bladder 114 does not obstruct or only slight obstructs bodily fluids from flowing through the fluid permeable membrane 130 to the fluid permeable support 132. For example, the bladder 114 may be positioned so, at most, only a small portion of the bladder 114 (e.g., at most 20%, at most 10%, or at most 5%) is not positioned between the fluid impermeable barrier 102 and the support 132.
In some examples, the fluid permeable membrane 130 may be optional. For example, the porous material 110 may include only the fluid permeable support 132. In such examples, the bladder 114 may be positioned within the fluid permeable support 132 since, for instance, at least some materials of the support 132 disclosed herein are flexible enough to accommodate the shape and/or size changes discussed herein. In some examples, the fluid permeable support 132 may be optionally omitted from the fluid collection assembly 100 and the porous material 110 may only include the fluid permeable membrane 130. In such examples, the bladder 114 may be positioned within the fluid permeable membrane 130.
In an embodiment, the fluid permeable membrane 130 and/or the fluid permeable support 132 are wicking materials. In such an embodiment, the fluid permeable support 132 may have a greater ability to wick the bodily fluids than the fluid permeable membrane 130, such as to move the bodily fluids inwardly from the fluid permeable membrane 130. In some examples, the wicking ability of the fluid permeable support 132 and the fluid permeable membrane 130 may be substantially the same. In an embodiment, the fluid permeable membrane 130 and/or the fluid permeable support 132 are non-wicking materials (e.g., absorbent and/or adsorbent materials).
In an embodiment, not shown, the fluid permeable membrane 130 and the fluid permeable support 132 may at least substantially completely fill the portions of the chamber 106 not occupied by the inflation device 112 and the conduit 128. In an embodiment, as shown in
The fluid reservoir 133 is a substantially unoccupied portion of the chamber 106. The fluid reservoir 133 may be defined between the fluid impermeable barrier 102 and at least one of the inflation device 112, the fluid permeable membrane 130, or the fluid permeable support 132. The bodily fluids in the chamber 106 may flow through the fluid permeable membrane 130 and/or fluid permeable support 132 to the fluid reservoir 133. The fluid reservoir 133 may retain of the bodily fluids. The bodily fluids in the chamber 106 may flow through the fluid permeable membrane 130 and/or fluid permeable support 132 and, optionally, to the fluid reservoir 133. The fluid impermeable barrier 102 may retain the bodily fluids in the fluid reservoir 133. The fluid reservoir 133 may be in a portion of the chamber 106 designed to be in a gravimetrically low point of the fluid collection assembly 100 when the fluid collection assembly 100 is worn.
The inflation devices disclosed herein may be positioned in locations of the fluid collection assemblies disclosed herein other than between the fluid permeable membrane and the fluid permeable support. For example,
Referring to
Referring to
Switching the fluid collection assembly 202b and the inflation barrier 234b between different states will have limited effect on the size and shape of the porous material 210b compared to the fluid impermeable barrier 130 shown in
Referring to
It is noted that the inflation devices disclosed herein may have positions other that the positions illustrated in
The inflation device 312 includes a bladder 314. The first bladder 314 includes one or more walls 316. The one or more walls 316 define a first inflation region 318a and a second inflation region 318b. The inflation device 312 includes at least one passageway 336 extending between and fluidly coupling the first inflation region 318a to the second inflation region 318b. For example, the one or more walls 316 defines the passageway 336. Inflation fluids present in the first inflation region 318a may flow to the second inflation region 318b by entering the passageway 336, flowing through the passage way 336, and then exiting the passageway 336 and vice versa. The pressure inside each of the first inflation region 318a and the second inflation region 318b remains the same thereby preventing over inflation or under inflation of one of the first inflation region 318a or the second inflation region 318b.
In an embodiment, the inflation device 312 may include a single valve 320 since the first inflation region 318a is in fluid communication with the second inflation region 318b. The valve 320 may be in direct fluid communication with one of the first inflation region 318a, the second inflation region 318b, or the passageway 336. However, it is noted that the inflation device 312 may include at least one valve 320 that is in direct fluid communication with at least two of the first inflation region 318a, the second inflation region 318b, or the passageway 336.
In an embodiment, inflation device 310 may include one or more additional inflation regions (not shown) that are in fluid communication with the first inflation region 318a and the second inflation region 318b through the passageway 336 or through one or more additional passageways. In an embodiment, the passageway 336 may include a passageway valve that selective permits or restricts fluid flow between the first inflation region 318a to the second inflation region 318b. For example, the passageway valve may be open (e.g., permit fluid flow between the first inflation region 318a and the second inflation region 318b) when it is desirable for the first inflation region 318a and the second inflation region 318b to exhibit the same pressure. However, the passageway valve may be closed when it is desirable to independently inflate at least one of the first inflation region 318a or the second inflation region 318b (e.g., when it is desirable for one of the first inflation region 318a or the second inflation region 318b to be inflated more than the other). The passageway valve may include any suitable valve, such as a mechanical valve or a clamp.
The fluid collection assemblies illustrated in
Regarding
The generally hour-glass shape of the fluid collection assembly 400a includes two opposing edges 442a, four apexes 444a at the ends of the edges 442a, and two concave surfaces 446a extending between adjacent apexes 444a. The opening 404a is formed on one edge 442a. The two apexes 444a that are most proximate to the opening 404a are configured to fit at least partially in the fold formed between the inner thighs and the rest of the pubic region of the patient. The concave surfaces 446a are configured to press against and generally correspond to the convex shape inner thighs of the patient. The ability of the two apexes 444a to fit at least partially into the fold formed between the inner thighs and the rest of the pubic region and the concave surfaces 446a to correspond to the concave inner thighs help secure the fluid collection assembly 400a to the patient, maintain the opening 404a against the vulva of the patient, and make the fluid collection assembly 400a more comfortable compared to some other shapes.
Regarding
The generally triangular cross-sectional shape of the fluid collection assembly 400b includes three edges 442b and three apexes 444b at the intersection of each edge 442b. The opening 404b is formed at one of the three apexes 444b which allows that porous material 410b to partially fit between the labia and to press more closely to the urethral opening of the patent. Positioning a portion of the porous material 410b between the labia helps secure the fluid collection assembly 400b to the patient.
The fluid collection assemblies shown in
The fluid collection assembly 600 includes a receptacle 654 and a sheath 656. The receptacle 654 is sized, shaped, and made of a material to be coupled to skin that surrounds the penis (mons pubis, testicles, perineum, etc.) and have the penis positioned therethrough. For example, the receptacle 654 may include an annular base 658 that defines an opening 660 in the receptacle 654. The annular base 658 is sized and shaped to be positioned around the penis and have the penis positioned therethrough. The annular base 658 may also be sized, shaped, made of a material, or otherwise configured to be coupled (e.g., adhesively attached, such as with a hydrogel adhesive) to the skin around the penis. In an example, the annular base 658 may exhibit the general shape or contours of the skin surface that the annular base 658 is selected to be coupled with. The annular base 658 may be flexible thereby allowing the annular base 658 to conform to any shape of the skin surface. The annular base 658 may include a laterally extending flange 662. The receptacle 654 also defines a hollowed region configured to receive (e.g., seal against) the sheath 656. For example, the receptacle 654 may include a longitudinally extending flange 664 that extends upwardly from the annular base 658. The longitudinally extending flange 664 may be tall enough to prevent the sheath 656 from being accidentally removed from the receptacle 654 (e.g., at least 0.25 cm tall, 1 cm tall, at least 9 cm tall, or at least 5 cm tall). The receptacle 654 is at a proximal region 666 (regarding a patient) of the fluid collection assembly 600.
The sheath 656 includes (e.g., may be formed from) a fluid impermeable barrier 602 sized and shaped to fit into the hollowed region of the receptacle 654. For example, the sheath 656 may be generally tubular or cup-shaped, as shown. The generally tubular or cup-shaped fluid impermeable barrier 602 may at least partially define the outer surface 624 of the sheath 656. The fluid impermeable barrier 602 may be similar or identical to the fluid impermeable barrier 102 as disclosed herein, in one or more aspects. For example, the fluid impermeable barrier 602 may be constructed of any of the materials disclosed herein for the fluid impermeable barrier 102. The fluid impermeable barrier 602 at least partially defines the chamber 606. For example, the inner surface 626 of the fluid impermeable barrier 602 at least partially defines the perimeter of the chamber 606. The chamber 606 may be similar or identical to the chamber 106 in one or more aspects. For example, the chamber 606 may at least temporarily retain fluids. As shown, the fluid collection assembly 600 may include at least one porous material 610. The porous material 610 may be similar or identical to the porous material 110 in one or more aspects. For example, the porous material 610 may include one or more of a fluid permeable membrane 630 or a fluid permeable support 632. The fluid impermeable barrier 602 may also define an opening 604 extending through the fluid impermeable barrier 602 configured to have a penis positioned therethrough.
The sheath 656 and fluid impermeable barrier 602 may also include at least one aperture 668 (e.g., vacuum relief hole) that allows the chamber 606 to remain substantially at atmospheric pressure. The at least one aperture 668 may be at any point on the sheath 656, such as near or nearer the opening 660. In some examples (not shown), the aperture 668 may extend through the cap 670 or be disposed beneath the cap 670. In some examples, the fluid collection assembly 600 may not include the aperture 668, such as when a more complete seal as desired for the chamber 606.
The sheath 656 also includes at least a portion of the conduit 628, such as at least partially disposed in the chamber 606. For example, the conduit 628 may extend from the sheath 656 at the distal region 672 to a proximal region 666 at least proximate to the opening 660. The proximal region 666 may be disposed near or on the skin around the penis or pubic area therearound. When a patient lays on their back, bodily fluids may aggregate near the opening 660 against the skin of the patient. The bodily fluids may be removed from the chamber 606 via the conduit 628.
In some examples, the fluid impermeable barrier 602 may be constructed of a material and/or have a thickness that allows the sheath 656 to collapse when placed under vacuum, such as to remove air around a penis in the fluid collection assembly 600 during use. In such examples, the conduit 628 may extend only to or into the distal region 672 in the chamber 606 (e.g., not through to the area adjacent the opening). In such examples, bodily fluids may be collected and removed from the fluid collection assembly 600 at the end nearest the aperture 668. In such examples, the at least one aperture may be located nearest the opening 660.
In an example, portions of the chamber 606 may be substantially empty due to the varying sizes and rigidity of the male penis. However, in some examples, the outermost regions of the chamber 606 (e.g., periphery of the interior regions of the sheath 656) may include porous material 610 (e.g., one or more of the fluid permeable membrane 630 and fluid permeable support 632). For example, the porous material 610 may be bonded to the inner surface 626 of the fluid impermeable barrier 602. The porous material 610 may be positioned (e.g., at the distal end of the chamber 606) to blunt a stream of urine from the penis thereby limiting splashing and/or to direct the fluid(s) to a selected region of the chamber 606. Since the chamber 606 is substantially empty (e.g., substantially the chamber 606 forms a reservoir), the fluids are likely to pool at a gravimetrically low point of the chamber 606. The gravimetrically low point of the chamber 606 may be at an intersection of the skin of an patient and the fluid collection assembly 600, a corner formed in the sheath 656, or another suitable location depending on the orientation of the patient.
The porous material 610 may include one or more of the fluid permeable membrane 630 or the fluid permeable support 632. The fluid permeable membrane 630 and the fluid permeable support 632 may be similar or identical to the fluid permeable membrane 130 or the fluid permeable support 132 as respectively disclosed herein, in one or more aspects such as material make-up or wicking ability. One or more of the fluid permeable membrane 630 or the fluid permeable support 632 may be disposed between the fluid impermeable barrier 602 and a penis inserted into the chamber 606. The fluid permeable membrane 630 may be positioned between the fluid impermeable barrier 602 and a penis inserted into the chamber 606, such as between the fluid permeable support 632 and penis of a wearer as shown. The fluid permeable support 632 may be positioned between the fluid permeable membrane 630 and the fluid impermeable barrier 602. The inner surface 626, optionally including the end of the chamber 606 substantially opposite the opening 604, may be covered with one or both the fluid permeable membrane 630 or the fluid permeable support 632. The fluid permeable support 632 or the fluid permeable membrane 630 may be affixed (e.g., adhered) to the fluid impermeable barrier 602. The fluid permeable support 632 or the fluid permeable membrane 630 may be affixed to each other. In some examples, the porous material 610 only includes the fluid permeable membrane 630 or the fluid permeable support 632.
The fluid collection assembly 600 includes one or more inflation devices in one or more portions thereof. For example, the fluid collection assembly 600 will be discusses as having a first inflation device 612a and a second inflation device 612b. However, it is noted that the fluid collection assembly 600 may only include a single inflation device (e.g., the first inflation device 612a, the second inflation device 612b, or another inflation device) or three or more inflation devices (e.g., the first inflation device 612a, a second inflation device 612b, and another inflation device). The inflation devices of the fluid collection assembly 600 may be similar or identical to any of the inflation devices disclosed herein in one or more aspects. For example, the first inflation device 612a may include at least one first bladder 614a and at least one first valve 620a and the second inflation device 612b may include at least one second bladder 614b and at least one second valve 620b.
The first inflation device 612a may be disposed on (as shown) or in the receptacle 654. In an embodiment, the first inflation device 612a increases the width (measure perpendicular to the longitudinal axis of the fluid collection assembly 600) of the receptacle when the pubic region of the patient is large enough to accommodate the increased width. The increase width of the receptacle 654 increases the surface area of the receptacle 654 that contacts the patient which may facilitate securement of the receptacle 654. For example, the increased surface area may allow for additional adhesive to be applied to the surface of the receptacle 654 that contacts the patient. In an embodiment, the first inflation device 612a changes the cross-sectional shape (measured perpendicular to the longitudinal axis of the fluid collection assembly 600) of the receptacle 654 which allows the receptacle 654 to conform to differently shaped pubic regions. In an embodiment, the first inflation device 612a increases a thickness of the receptacle 654 which may increase a contact pressure that, at least partially, secures the receptacle 654 to the pubic region.
The second inflation device 612b may be disposed on or in (as shown) the sheath 656. The second inflation device 612b may be configured to decrease a width of the chamber 606. For example, decreasing the width of the chamber 606 may cause the sheath 656 to contact a smaller diameter penis, a non-erect penis, or to conform to a penis that is transitioning between erect and non-erect states. Decreasing the width of the chamber 606 may inhibit bodily fluids from flowing away from the fluid outlet 608 thereby facilitating removal of the bodily fluids from the chamber 606.
In some examples, the fluid collection assembly 600 includes a cap 670 at a distal region 672. The cap 670 defines an fluid outlet 608 through which the fluids may be removed from the fluid collection assembly 600. The fluid outlet 608 is in fluid communication with the chamber 606. The cap 670 may be disposed over at least a portion of the distal region 672 of one or more of the fluid impermeable barrier 602 or the porous material 610. The cap 670 may be made of a polymer, rubber, or any other fluid impermeable material. The cap 670 may be attached to one or more of the fluid impermeable barrier 602, the porous material 610, or the conduit 628. The cap 670 may have a laterally extending flange 674 and a longitudinally extending flange 676. The laterally extending flange 674 may cover at least a portion of the distal region 672 of the fluid collection assembly 600. The longitudinally extending flange 676 may laterally extend a distance from the sheath 656. The longitudinally extending flange 676 is sized and configured to receive and fluidly seal against the conduit 628, such as within the fluid outlet 608. The conduit 628 may extend a distance within or through the cap 670, such as to the porous material 610, through the porous material 610, or to a point set-off from the porous material 610. In an example, the cap 670 may define a reservoir 678.
The reservoir 678 is an unoccupied portion of device such as in the cap 670 and is void of other material. In some examples, the reservoir 678 is defined at least partially by the porous material 610 and the cap 670. During use, the fluids in the chamber 606 may flow through the porous material 610 to the reservoir 678. The reservoir 678 may store at least some fluids and/or position the fluids for removal by the conduit 628. In some examples, at least a portion of the porous material 610 may extend continuously between at least a portion of the opening of the fluid outlet 608 and chamber 606 to wick any fluid from the opening directly to the reservoir 678.
In some examples (not shown), the fluid impermeable barrier 602 may be disposed on or over the cap 670, such as enclosing the cap 670 within the chamber 606.
In some examples, the sheath 656 may include at least a portion of the conduit 628, such as at least partially disposed in the chamber 606. For example, the conduit 628 may extend from the sheath 656 to a region at least proximate to the opening 660. The inlet of the conduit 628 may be positioned adjacent to the annular base 658. The inlet of the conduit 628 may be positioned to be adjacent or proximate to the gravimetrically low point of the chamber 606, such as adjacent to the annular base 658. For example, the inlet may be co-extensive with or offset from the opening 660. In examples, the inlet may be positioned adjacent to the distal region 672 of the sheath 656 (e.g., substantially opposite the opening).
The proximal region 666 may be disposed near or on the skin around the penis and the inlet of the conduit 628 may be positioned in the proximal region 666. The outlet of the conduit 628 may be directly or indirectly coupled to a vacuum source. Fluid may be removed from the proximal region 666 of the chamber 606 via the conduit 628.
The receptacle 654, the sheath 656, the cap 670, and the conduit 628 may be attached together using any suitable method. For example, at least two of the receptacle 654, the sheath 656, the cap 670, or the conduit 628 may be attached using at least one of an interference fit, an adhesive, stitching, welding (e.g., ultrasonic welding), tape, any other suitable method, or combinations thereof.
In some examples (not shown), the fluid collection assembly 600 may have a one piece design, with one or more of the sheath 656, the receptacle 654, and the cap 670 being a single, integrally formed piece.
Also as shown, the conduit 628 may be at least partially disposed with the chamber of a fluid collection assembly. The conduit 628 may extend from the distal region 672 to the proximal region 666. For example, the conduit 628 may extend through the cap 670 to a point adjacent to the receptacle 654. The conduit 628 is sized and positioned to be coupled to a fluid storage container or the vacuum source (
In some examples, the vacuum source may be remotely located from the fluid collection assembly 600. In such examples, the conduit 628 may be fluidly connected to the fluid storage container, which may be disposed between the vacuum source and the fluid collection assembly 600.
During operation, a male using the fluid collection assembly 600 may discharge fluid(s) (e.g., urine) into the chamber 606. The fluid(s) may pool or otherwise be collected in the chamber 606. At least some of the fluid(s) may be pulled through the interior of the conduit 628 via the inlet. The fluid may be drawn out of the fluid collection assembly 600 via the vacuum/suction provided by the vacuum source. During operation, the aperture 668 may substantially maintain the pressure in the chamber 606 at atmospheric pressure even though fluid is introduced into and removed from the chamber 606.
Additional examples of male fluid collection assemblies that may include one or more inflation devices are disclosed in U.S. patent application Ser. No. 16/433,773 filed on Jun. 6, 2019, the disclose of which is incorporated herein, in its entirety, by this reference.
The suction force may be applied to the outlet of the conduit 728 by the vacuum source 709 either directly or indirectly. The suction force may be applied indirectly via the fluid storage container 707. For example, the outlet of the conduit 728 may be disposed within the fluid storage container 707 and an additional conduit 728 may extend from the fluid storage container 707 to the vacuum source 709. The vacuum source 709 may apply suction to the fluid collection assembly 700 via the fluid storage container 707. The suction force may be applied directly via the vacuum source 709. For example, the outlet of the conduit 728 may be disposed within the vacuum source 709. An additional conduit 728 may extend from the vacuum source 709 to a point outside of the fluid collection assembly 700, such as to the fluid storage container 707. In such examples, the vacuum source 709 may be disposed between the fluid collection assembly 700 and the fluid storage container 707.
The fluid collection assembly 700 may be similar or identical to any of the fluid collection assemblies disclosed herein in one or more aspects. The fluid collection assembly 700 may be shaped and sized to be positioned adjacent to a female urethral opening or receive a penis.
The fluid storage container 707 is sized and shaped to retain a fluid. The fluid storage container 707 may include a bag (e.g., drainage bag), a bottle or cup (e.g., collection jar), or any other enclosed container for storing bodily fluid(s) such as urine. In some examples, the conduit 728 may extend from the fluid collection assembly 700 and attach to the fluid storage container 707 at a first point. An additional conduit 728 may attach to the fluid storage container 707 at a second point thereon and may extend and attach to the vacuum source 709. A vacuum (e.g., suction) may be drawn through fluid collection assembly 700 via the fluid storage container 707. Fluid, such as urine, may be drained from the fluid collection assembly 700 using the vacuum source 709.
The vacuum source 709 may include one or more of a manual vacuum pump, and electric vacuum pump, a diaphragm pump, a centrifugal pump, a displacement pump, a magnetically driven pump, a peristaltic pump, or any pump configured to produce a vacuum. The vacuum source 709 may provide a vacuum or suction to remove fluid from the fluid collection assembly 700. In some examples, the vacuum source 709 may be powered by one or more of a power cord (e.g., connected to a power socket), one or more batteries, or even manual power (e.g., a hand operated vacuum pump). In some examples, the vacuum source 709 may be sized and shaped to fit outside of, on, or within the fluid collection assembly 700. For example, the vacuum source 709 may include one or more miniaturized pumps or one or more micro pumps. The vacuum sources 709 disclosed herein may include one or more of a switch, a button, a plug, a remote, or any other device suitable to activate the vacuum source 709.
While various aspects and embodiments have been disclosed herein, other aspects and embodiments are contemplated. The various aspects and embodiments disclosed herein are for purposes of illustration and are not intended to be limiting.
Terms of degree (e.g., “about,” “substantially,” “generally,” etc.) indicate structurally or functionally insignificant variations. In an example, when the term of degree is included with a term indicating quantity, the term of degree is interpreted to mean±10%, ±5%, or +2% of the term indicating quantity. In an example, when the term of degree is used to modify a shape, the term of degree indicates that the shape being modified by the term of degree has the appearance of the disclosed shape. For instance, the term of degree may be used to indicate that the shape may have rounded corners instead of sharp corners, curved edges instead of straight edges, one or more protrusions extending therefrom, is oblong, is the same as the disclosed shape, etc.
| Number | Name | Date | Kind |
|---|---|---|---|
| 1032841 | Koenig | Jul 1912 | A |
| 1178644 | Johnson | Apr 1916 | A |
| 1742080 | Jones | Dec 1929 | A |
| 1979899 | Obrien et al. | Nov 1934 | A |
| 2262772 | Peder | Nov 1941 | A |
| 2326881 | Packer | Aug 1943 | A |
| 2379346 | Farrell | Jun 1945 | A |
| 2613670 | Edward | Oct 1952 | A |
| 2616426 | Adele | Nov 1952 | A |
| 2644234 | Earl | Jul 1953 | A |
| 2648335 | Chambers | Aug 1953 | A |
| 2859786 | Tupper | Nov 1958 | A |
| 2944551 | Carl | Jul 1960 | A |
| 2968046 | Duke | Jan 1961 | A |
| 2971512 | Reinhardt | Feb 1961 | A |
| 3032038 | Swinn | May 1962 | A |
| 3077883 | Hill | Feb 1963 | A |
| 3087938 | Hans et al. | Apr 1963 | A |
| 3169528 | Knox et al. | Feb 1965 | A |
| 3194238 | Breece | Jul 1965 | A |
| 3198994 | Hildebrandt et al. | Aug 1965 | A |
| 3221742 | Egon | Dec 1965 | A |
| 3312221 | Overment | Apr 1967 | A |
| 3312981 | McGuire et al. | Apr 1967 | A |
| 3349768 | Keane | Oct 1967 | A |
| 3362590 | Gene | Jan 1968 | A |
| 3366116 | Huck | Jan 1968 | A |
| 3398848 | Donovan | Aug 1968 | A |
| 3400717 | Bruce et al. | Sep 1968 | A |
| 3406688 | Bruce | Oct 1968 | A |
| 3424163 | Gravdahl | Jan 1969 | A |
| 3425471 | Yates | Feb 1969 | A |
| 3511241 | Lee | May 1970 | A |
| 3512185 | Ellis | May 1970 | A |
| 3520300 | Flower | Jul 1970 | A |
| 3528423 | Lee | Sep 1970 | A |
| 3613123 | Langstrom | Oct 1971 | A |
| 3648700 | Warner | Mar 1972 | A |
| 3651810 | Ormerod | Mar 1972 | A |
| 3661155 | Lindan | May 1972 | A |
| 3699815 | Holbrook | Oct 1972 | A |
| 3726277 | Hirschman | Apr 1973 | A |
| 3742952 | Magers | Jul 1973 | A |
| 3757355 | Allen et al. | Sep 1973 | A |
| 3788324 | Lim | Jan 1974 | A |
| 3843016 | Bornhorst et al. | Oct 1974 | A |
| 3863638 | Rogers et al. | Feb 1975 | A |
| 3863798 | Kurihara et al. | Feb 1975 | A |
| 3864759 | Horiuchi | Feb 1975 | A |
| 3881486 | Fenton | May 1975 | A |
| 3881489 | Hartwell | May 1975 | A |
| 3915189 | Holbrook et al. | Oct 1975 | A |
| 3998228 | Poidomani | Dec 1976 | A |
| 3999550 | Martin | Dec 1976 | A |
| 4015604 | Csillag | Apr 1977 | A |
| 4020843 | Kanall | May 1977 | A |
| 4022213 | Stein | May 1977 | A |
| 4027776 | Douglas | Jun 1977 | A |
| 4116197 | Bermingham | Sep 1978 | A |
| 4180178 | Turner | Dec 1979 | A |
| 4187953 | Turner | Feb 1980 | A |
| 4194508 | Anderson | Mar 1980 | A |
| 4200102 | Duhamel et al. | Apr 1980 | A |
| 4202058 | Anderson | May 1980 | A |
| 4233025 | Larson et al. | Nov 1980 | A |
| 4233978 | Hickey | Nov 1980 | A |
| 4246901 | Frosch et al. | Jan 1981 | A |
| 4257418 | Hessner | Mar 1981 | A |
| 4270539 | Frosch et al. | Jun 1981 | A |
| 4281655 | Terauchi | Aug 1981 | A |
| 4292916 | Bradley et al. | Oct 1981 | A |
| 4352356 | Tong | Oct 1982 | A |
| 4360933 | Kimura et al. | Nov 1982 | A |
| 4365363 | Windauer | Dec 1982 | A |
| 4387726 | Denard | Jun 1983 | A |
| 4425130 | DesMarais | Jan 1984 | A |
| 4446986 | Bowen et al. | May 1984 | A |
| 4453938 | Brendling | Jun 1984 | A |
| 4457314 | Knowles | Jul 1984 | A |
| 4476879 | Jackson | Oct 1984 | A |
| 4526688 | Schmidt et al. | Jul 1985 | A |
| 4528703 | Kraus | Jul 1985 | A |
| D280438 | Wendt | Sep 1985 | S |
| 4551141 | McNeil | Nov 1985 | A |
| 4553968 | Komis | Nov 1985 | A |
| 4581026 | Schneider | Apr 1986 | A |
| 4610675 | Triunfol | Sep 1986 | A |
| 4620333 | Ritter | Nov 1986 | A |
| 4626250 | Schneider | Dec 1986 | A |
| 4627846 | Ternstroem | Dec 1986 | A |
| 4631061 | Martin | Dec 1986 | A |
| 4650477 | Johnson | Mar 1987 | A |
| 4656675 | Fajnsztajn | Apr 1987 | A |
| 4681570 | Dalton | Jul 1987 | A |
| 4681577 | Stern et al. | Jul 1987 | A |
| 4692160 | Nussbaumer | Sep 1987 | A |
| 4707864 | Ikematsu et al. | Nov 1987 | A |
| 4713065 | Koot | Dec 1987 | A |
| 4713066 | Komis | Dec 1987 | A |
| 4743236 | Manschot | May 1988 | A |
| 4747166 | Kuntz | May 1988 | A |
| 4752944 | Conrads et al. | Jun 1988 | A |
| 4769215 | Ehrenkranz | Sep 1988 | A |
| 4771484 | Mozell | Sep 1988 | A |
| 4772280 | Rooyakkers | Sep 1988 | A |
| 4790830 | Hamacher | Dec 1988 | A |
| 4790835 | Elias | Dec 1988 | A |
| 4791686 | Taniguchi et al. | Dec 1988 | A |
| 4795449 | Schneider et al. | Jan 1989 | A |
| 4798603 | Meyer et al. | Jan 1989 | A |
| 4799928 | Crowley | Jan 1989 | A |
| 4804377 | Hanifl et al. | Feb 1989 | A |
| 4812053 | Bhattacharjee | Mar 1989 | A |
| 4813943 | Smith | Mar 1989 | A |
| 4820297 | Kaufman et al. | Apr 1989 | A |
| 4846818 | Keldahl et al. | Jul 1989 | A |
| 4846909 | Klug et al. | Jul 1989 | A |
| 4865595 | Heyden | Sep 1989 | A |
| 4880417 | Yabrov et al. | Nov 1989 | A |
| 4882794 | Stewart | Nov 1989 | A |
| 4883465 | Brennan | Nov 1989 | A |
| 4886498 | Newton | Dec 1989 | A |
| 4886508 | Washington | Dec 1989 | A |
| 4886509 | Mattsson | Dec 1989 | A |
| 4889532 | Metz et al. | Dec 1989 | A |
| 4889533 | Beecher | Dec 1989 | A |
| 4903254 | Haas | Feb 1990 | A |
| 4904248 | Vaillancourt | Feb 1990 | A |
| 4905692 | More | Mar 1990 | A |
| 4936838 | Cross et al. | Jun 1990 | A |
| 4955922 | Terauchi | Sep 1990 | A |
| 4957487 | Gerow | Sep 1990 | A |
| 4965460 | Tanaka et al. | Oct 1990 | A |
| 4987849 | Sherman | Jan 1991 | A |
| 5002541 | Conkling et al. | Mar 1991 | A |
| 5004463 | Nigay | Apr 1991 | A |
| 5031248 | Kemper | Jul 1991 | A |
| 5045077 | Blake | Sep 1991 | A |
| 5045283 | Patel | Sep 1991 | A |
| 5049144 | Payton | Sep 1991 | A |
| 5053339 | Patel | Oct 1991 | A |
| 5058088 | Haas et al. | Oct 1991 | A |
| 5071347 | McGuire | Dec 1991 | A |
| 5078707 | Peter | Jan 1992 | A |
| 5084037 | Barnett | Jan 1992 | A |
| 5100396 | Zamierowski | Mar 1992 | A |
| 5112324 | Wallace | May 1992 | A |
| 5147301 | Ruvio | Sep 1992 | A |
| 5176667 | Debring | Jan 1993 | A |
| 5195997 | Carns | Mar 1993 | A |
| 5203699 | McGuire | Apr 1993 | A |
| 5244458 | Takasu | Sep 1993 | A |
| 5246454 | Peterson | Sep 1993 | A |
| 5267988 | Farkas | Dec 1993 | A |
| 5275307 | Freese | Jan 1994 | A |
| 5294983 | Ersoz et al. | Mar 1994 | A |
| 5295983 | Kubo | Mar 1994 | A |
| 5300052 | Kubo | Apr 1994 | A |
| 5312383 | Kubalak | May 1994 | A |
| 5318550 | Cermak et al. | Jun 1994 | A |
| 5330459 | Lavon et al. | Jul 1994 | A |
| 5340840 | Park et al. | Aug 1994 | A |
| 5382244 | Telang | Jan 1995 | A |
| 5409014 | Napoli et al. | Apr 1995 | A |
| 5411495 | Willingham | May 1995 | A |
| 5423784 | Metz | Jun 1995 | A |
| 5456246 | Schmieding et al. | Oct 1995 | A |
| 5466229 | Elson et al. | Nov 1995 | A |
| 5478334 | Bernstein | Dec 1995 | A |
| 5499977 | Marx | Mar 1996 | A |
| 5543042 | Filan et al. | Aug 1996 | A |
| D373928 | Green | Sep 1996 | S |
| 5582604 | Ahr et al. | Dec 1996 | A |
| 5592950 | Kopelowicz | Jan 1997 | A |
| 5605161 | Cross | Feb 1997 | A |
| 5618277 | Goulter | Apr 1997 | A |
| 5628735 | Skow | May 1997 | A |
| 5636643 | Argenta et al. | Jun 1997 | A |
| 5637104 | Ball et al. | Jun 1997 | A |
| 5674212 | Osborn et al. | Oct 1997 | A |
| 5678564 | Lawrence et al. | Oct 1997 | A |
| 5678654 | Uzawa | Oct 1997 | A |
| 5687429 | Rahlff | Nov 1997 | A |
| 5695485 | Duperret et al. | Dec 1997 | A |
| 5700254 | McDowall et al. | Dec 1997 | A |
| 5752944 | Dann et al. | May 1998 | A |
| 5772644 | Bark et al. | Jun 1998 | A |
| 5792132 | Garcia | Aug 1998 | A |
| 5827243 | Palestrant | Oct 1998 | A |
| 5827247 | Kay | Oct 1998 | A |
| 5827250 | Fujioka et al. | Oct 1998 | A |
| 5827257 | Fujioka et al. | Oct 1998 | A |
| D401699 | Herchenbach et al. | Nov 1998 | S |
| 5865378 | Hollinshead et al. | Feb 1999 | A |
| 5876393 | Ahr et al. | Mar 1999 | A |
| 5887291 | Bellizzi | Mar 1999 | A |
| 5894608 | Birbara | Apr 1999 | A |
| D409303 | Oepping | May 1999 | S |
| 5911222 | Lawrence et al. | Jun 1999 | A |
| 5957904 | Holland | Sep 1999 | A |
| 5968026 | Osborn et al. | Oct 1999 | A |
| 5972505 | Phillips et al. | Oct 1999 | A |
| 6039060 | Rower | Mar 2000 | A |
| 6050983 | Moore et al. | Apr 2000 | A |
| 6059762 | Boyer et al. | May 2000 | A |
| 6063064 | Tuckey et al. | May 2000 | A |
| 6098625 | Winkler | Aug 2000 | A |
| 6105174 | Karlsten et al. | Aug 2000 | A |
| 6113582 | Dwork | Sep 2000 | A |
| 6117163 | Bierman | Sep 2000 | A |
| 6123398 | Arai et al. | Sep 2000 | A |
| 6129718 | Wada et al. | Oct 2000 | A |
| 6131964 | Sareshwala | Oct 2000 | A |
| 6152902 | Christian et al. | Nov 2000 | A |
| 6164569 | Hollinshead et al. | Dec 2000 | A |
| 6177606 | Etheredge et al. | Jan 2001 | B1 |
| 6209142 | Mattsson et al. | Apr 2001 | B1 |
| 6248096 | Dwork et al. | Jun 2001 | B1 |
| 6263887 | Dunn | Jul 2001 | B1 |
| 6311339 | Kraus | Nov 2001 | B1 |
| 6336919 | Davis et al. | Jan 2002 | B1 |
| 6338729 | Wada et al. | Jan 2002 | B1 |
| 6352525 | Wakabayashi | Mar 2002 | B1 |
| 6394988 | Hashimoto | May 2002 | B1 |
| 6398742 | Kim | Jun 2002 | B1 |
| 6406463 | Brown | Jun 2002 | B1 |
| 6409712 | Dutari et al. | Jun 2002 | B1 |
| 6416500 | Wada et al. | Jul 2002 | B1 |
| 6423045 | Wise et al. | Jul 2002 | B1 |
| 6428521 | Droll | Aug 2002 | B1 |
| 6428522 | Dipalma et al. | Aug 2002 | B1 |
| 6475198 | Lipman et al. | Nov 2002 | B1 |
| 6479726 | Cole et al. | Nov 2002 | B1 |
| 6491673 | Palumbo et al. | Dec 2002 | B1 |
| 6508794 | Palumbo et al. | Jan 2003 | B1 |
| 6524292 | Dipalma et al. | Feb 2003 | B1 |
| 6540729 | Wada et al. | Apr 2003 | B1 |
| 6547771 | Robertson et al. | Apr 2003 | B2 |
| 6569133 | Cheng et al. | May 2003 | B2 |
| D476518 | Doppelt | Jul 2003 | S |
| 6592560 | Snyder et al. | Jul 2003 | B2 |
| 6610038 | Dipalma et al. | Aug 2003 | B1 |
| 6618868 | Minnick | Sep 2003 | B2 |
| 6620142 | Flueckiger | Sep 2003 | B1 |
| 6629651 | Male et al. | Oct 2003 | B1 |
| 6635038 | Scovel | Oct 2003 | B2 |
| 6652495 | Walker | Nov 2003 | B1 |
| 6666850 | Ahr et al. | Dec 2003 | B1 |
| 6685684 | Falconer | Feb 2004 | B1 |
| 6695828 | Dipalma et al. | Feb 2004 | B1 |
| 6700034 | Lindsay et al. | Mar 2004 | B1 |
| 6702793 | Sweetser et al. | Mar 2004 | B1 |
| 6706027 | Harvie et al. | Mar 2004 | B2 |
| 6732384 | Scott | May 2004 | B2 |
| 6736977 | Hall et al. | May 2004 | B1 |
| 6740066 | Wolff et al. | May 2004 | B2 |
| 6764477 | Chen et al. | Jul 2004 | B1 |
| 6783519 | Samuelsson | Aug 2004 | B2 |
| 6796974 | Palumbo et al. | Sep 2004 | B2 |
| 6814547 | Childers et al. | Nov 2004 | B2 |
| 6849065 | Schmidt et al. | Feb 2005 | B2 |
| 6857137 | Otto | Feb 2005 | B2 |
| 6885690 | Aggerstam et al. | Apr 2005 | B2 |
| 6888044 | Fell et al. | May 2005 | B2 |
| 6893425 | Dunn et al. | May 2005 | B2 |
| 6912737 | Ernest et al. | Jul 2005 | B2 |
| 6918899 | Harvie | Jul 2005 | B2 |
| 6979324 | Bybordi et al. | Dec 2005 | B2 |
| 7018366 | Easter | Mar 2006 | B2 |
| 7066411 | Male et al. | Jun 2006 | B2 |
| 7122023 | Hinoki | Oct 2006 | B1 |
| 7125399 | Miskie | Oct 2006 | B2 |
| 7131964 | Harvie | Nov 2006 | B2 |
| 7135012 | Harvie | Nov 2006 | B2 |
| 7141043 | Harvie | Nov 2006 | B2 |
| D533972 | La | Dec 2006 | S |
| 7160273 | Greter et al. | Jan 2007 | B2 |
| 7171699 | Ernest et al. | Feb 2007 | B2 |
| 7171871 | Kozak | Feb 2007 | B2 |
| 7179951 | Krishnaswamy-Mirle et al. | Feb 2007 | B2 |
| 7181781 | Trabold et al. | Feb 2007 | B1 |
| 7186245 | Cheng et al. | Mar 2007 | B1 |
| 7192424 | Cooper | Mar 2007 | B2 |
| 7220250 | Suzuki et al. | May 2007 | B2 |
| D562975 | Otto | Feb 2008 | S |
| 7335189 | Harvie | Feb 2008 | B2 |
| 7358282 | Krueger et al. | Apr 2008 | B2 |
| 7390320 | Machida et al. | Jun 2008 | B2 |
| 7438706 | Koizumi et al. | Oct 2008 | B2 |
| 7488310 | Yang | Feb 2009 | B2 |
| 7491194 | Oliwa | Feb 2009 | B1 |
| D591106 | Dominique et al. | Apr 2009 | S |
| 7513381 | Heng et al. | Apr 2009 | B2 |
| 7520872 | Biggie et al. | Apr 2009 | B2 |
| D593801 | Wilson et al. | Jun 2009 | S |
| 7540364 | Sanderson | Jun 2009 | B2 |
| 7585293 | Vermaak | Sep 2009 | B2 |
| 7588560 | Dunlop | Sep 2009 | B1 |
| 7665359 | Barber | Feb 2010 | B2 |
| 7682347 | Parks et al. | Mar 2010 | B2 |
| 7687004 | Allen | Mar 2010 | B2 |
| 7695459 | Gilbert et al. | Apr 2010 | B2 |
| 7695460 | Wada et al. | Apr 2010 | B2 |
| 7699818 | Gilbert | Apr 2010 | B2 |
| 7699831 | Bengtson et al. | Apr 2010 | B2 |
| 7722584 | Tanaka et al. | May 2010 | B2 |
| 7727206 | Gorres | Jun 2010 | B2 |
| 7740620 | Gilbert et al. | Jun 2010 | B2 |
| 7749205 | Tazoe et al. | Jul 2010 | B2 |
| 7755497 | Wada et al. | Jul 2010 | B2 |
| 7766887 | Burns et al. | Aug 2010 | B2 |
| D625407 | Koizumi et al. | Oct 2010 | S |
| 7806879 | Brooks et al. | Oct 2010 | B2 |
| 7811272 | Lindsay et al. | Oct 2010 | B2 |
| 7815067 | Matsumoto et al. | Oct 2010 | B2 |
| 7833169 | Hannon | Nov 2010 | B2 |
| 7857806 | Karpowicz et al. | Dec 2010 | B2 |
| 7866942 | Harvie | Jan 2011 | B2 |
| 7871385 | Levinson et al. | Jan 2011 | B2 |
| 7875010 | Frazier et al. | Jan 2011 | B2 |
| 7901389 | Mombrinie | Mar 2011 | B2 |
| 7927320 | Goldwasser et al. | Apr 2011 | B2 |
| 7927321 | Marland | Apr 2011 | B2 |
| 7931634 | Swiecicki et al. | Apr 2011 | B2 |
| 7939706 | Okabe et al. | May 2011 | B2 |
| 7946443 | Stull et al. | May 2011 | B2 |
| 7947025 | Buglino et al. | May 2011 | B2 |
| 7963419 | Burney et al. | Jun 2011 | B2 |
| 7976519 | Bubb et al. | Jul 2011 | B2 |
| 7993318 | Olsson et al. | Aug 2011 | B2 |
| 8015627 | Baker et al. | Sep 2011 | B2 |
| 8028460 | Williams | Oct 2011 | B2 |
| 8047398 | Dimartino et al. | Nov 2011 | B2 |
| 8083094 | Caulfield et al. | Dec 2011 | B2 |
| 8128608 | Thevenin | Mar 2012 | B2 |
| 8181651 | Pinel | May 2012 | B2 |
| 8181819 | Burney et al. | May 2012 | B2 |
| 8211063 | Bierman et al. | Jul 2012 | B2 |
| 8221369 | Parks et al. | Jul 2012 | B2 |
| 8241262 | Mahnensmith | Aug 2012 | B2 |
| 8277426 | Wilcox et al. | Oct 2012 | B2 |
| 8287508 | Sanchez | Oct 2012 | B1 |
| 8303554 | Tsai et al. | Nov 2012 | B2 |
| 8322565 | Caulfield et al. | Dec 2012 | B2 |
| 8337477 | Parks et al. | Dec 2012 | B2 |
| D674241 | Bickert et al. | Jan 2013 | S |
| 8343122 | Gorres | Jan 2013 | B2 |
| 8353074 | Krebs | Jan 2013 | B2 |
| 8353886 | Bester et al. | Jan 2013 | B2 |
| D676241 | Merrill | Feb 2013 | S |
| 8388588 | Wada et al. | Mar 2013 | B2 |
| D679807 | Burgess et al. | Apr 2013 | S |
| 8425482 | Khoubnazar | Apr 2013 | B2 |
| 8449510 | Martini et al. | May 2013 | B2 |
| D684260 | Lund et al. | Jun 2013 | S |
| 8470230 | Caulfield et al. | Jun 2013 | B2 |
| 8479941 | Matsumoto et al. | Jul 2013 | B2 |
| 8479949 | Henkel | Jul 2013 | B2 |
| 8500719 | Simpson et al. | Aug 2013 | B1 |
| 8512301 | Ma | Aug 2013 | B2 |
| 8529530 | Koch et al. | Sep 2013 | B2 |
| 8535284 | Joder et al. | Sep 2013 | B2 |
| 8546639 | Wada et al. | Oct 2013 | B2 |
| 8551075 | Bengtson | Oct 2013 | B2 |
| 8568376 | Delattre et al. | Oct 2013 | B2 |
| D694404 | Burgess et al. | Nov 2013 | S |
| 8585683 | Bengtson et al. | Nov 2013 | B2 |
| 8586583 | Hamblin et al. | Nov 2013 | B2 |
| 8652112 | Johannison et al. | Feb 2014 | B2 |
| D702973 | Norland et al. | Apr 2014 | S |
| 8703032 | Menon et al. | Apr 2014 | B2 |
| D704330 | Cicatelli | May 2014 | S |
| D704510 | Mason et al. | May 2014 | S |
| D705423 | Walsh Cutler | May 2014 | S |
| D705926 | Burgess et al. | May 2014 | S |
| 8714394 | Wulf | May 2014 | B2 |
| 8715267 | Bengtson et al. | May 2014 | B2 |
| 8757425 | Copeland | Jun 2014 | B2 |
| 8777032 | Biesecker et al. | Jul 2014 | B2 |
| 8808260 | Koch et al. | Aug 2014 | B2 |
| 8864730 | Conway et al. | Oct 2014 | B2 |
| 8881923 | Higginson | Nov 2014 | B2 |
| 8882731 | Suzuki et al. | Nov 2014 | B2 |
| 8936585 | Carson et al. | Jan 2015 | B2 |
| D729581 | Boroski | May 2015 | S |
| 9028460 | Medeiros | May 2015 | B2 |
| 9056698 | Noer | Jun 2015 | B2 |
| 9078792 | Ruiz | Jul 2015 | B2 |
| 9173602 | Gilbert | Nov 2015 | B2 |
| 9173799 | Tanimoto et al. | Nov 2015 | B2 |
| 9187220 | Biesecker et al. | Nov 2015 | B2 |
| 9199772 | Krippendorf | Dec 2015 | B2 |
| 9233020 | Matsumiya | Jan 2016 | B2 |
| 9248058 | Conway et al. | Feb 2016 | B2 |
| 9308118 | Dupree et al. | Apr 2016 | B1 |
| 9309029 | Incorvia et al. | Apr 2016 | B2 |
| 9333281 | Giezendanner et al. | May 2016 | B2 |
| 9382047 | Schmidtner et al. | Jul 2016 | B2 |
| 9456937 | Ellis | Oct 2016 | B2 |
| 9480595 | Baham et al. | Nov 2016 | B2 |
| 9517865 | Albers et al. | Dec 2016 | B2 |
| D777941 | Piramoon | Jan 2017 | S |
| 9533806 | Ding et al. | Jan 2017 | B2 |
| 9550611 | Hodge | Jan 2017 | B2 |
| 9555930 | Campbell et al. | Jan 2017 | B2 |
| 9623159 | Locke | Apr 2017 | B2 |
| D789522 | Burgess et al. | Jun 2017 | S |
| 9687849 | Bruno et al. | Jun 2017 | B2 |
| 9694949 | Hendricks et al. | Jul 2017 | B2 |
| 9713547 | Lee et al. | Jul 2017 | B2 |
| 9788992 | Harvie | Oct 2017 | B2 |
| D804907 | Sandoval | Dec 2017 | S |
| 9868564 | McGirr et al. | Jan 2018 | B2 |
| D814239 | Arora | Apr 2018 | S |
| D817484 | Lafond | May 2018 | S |
| 10037640 | Gordon | Jul 2018 | B2 |
| 10058470 | Phillips | Aug 2018 | B2 |
| 10098990 | Koch et al. | Oct 2018 | B2 |
| D835264 | Mozzicato et al. | Dec 2018 | S |
| D835779 | Mozzicato et al. | Dec 2018 | S |
| D840533 | Mozzicato et al. | Feb 2019 | S |
| D840534 | Mozzicato et al. | Feb 2019 | S |
| 10225376 | Perez Martinez | Mar 2019 | B2 |
| 10226376 | Sanchez et al. | Mar 2019 | B2 |
| D848612 | Mozzicato et al. | May 2019 | S |
| 10307305 | Hodges | Jun 2019 | B1 |
| 10335121 | Desai | Jul 2019 | B2 |
| D856512 | Cowart et al. | Aug 2019 | S |
| 10376406 | Newton | Aug 2019 | B2 |
| 10376407 | Newton | Aug 2019 | B2 |
| 10390989 | Sanchez et al. | Aug 2019 | B2 |
| D858144 | Fu | Sep 2019 | S |
| 10406039 | Villarreal | Sep 2019 | B2 |
| 10407222 | Allen | Sep 2019 | B2 |
| 10478356 | Griffin | Nov 2019 | B2 |
| 10538366 | Pentelovitch et al. | Jan 2020 | B2 |
| 10569938 | Zhao et al. | Feb 2020 | B2 |
| 10577156 | Dagnelie et al. | Mar 2020 | B2 |
| 10618721 | Vazin | Apr 2020 | B2 |
| D884390 | Wang | May 2020 | S |
| 10669079 | Freedman et al. | Jun 2020 | B2 |
| D892315 | Airy | Aug 2020 | S |
| 10730672 | Bertram et al. | Aug 2020 | B2 |
| 10737848 | Philip et al. | Aug 2020 | B2 |
| 10765854 | Law et al. | Sep 2020 | B2 |
| 10766670 | Kittmann | Sep 2020 | B2 |
| 10799386 | Harrison | Oct 2020 | B1 |
| D901214 | Hu | Nov 2020 | S |
| 10857025 | Davis et al. | Dec 2020 | B2 |
| 10865017 | Cowart et al. | Dec 2020 | B1 |
| 10889412 | West et al. | Jan 2021 | B2 |
| 10913581 | Stahlecker | Feb 2021 | B2 |
| D912244 | Rehm et al. | Mar 2021 | S |
| 10952889 | Newton et al. | Mar 2021 | B2 |
| 10973678 | Newton et al. | Apr 2021 | B2 |
| 10974874 | Ragias et al. | Apr 2021 | B2 |
| 11000401 | Ecklund et al. | May 2021 | B2 |
| D923365 | Wang | Jun 2021 | S |
| 11026829 | Harvie | Jun 2021 | B2 |
| 11027900 | Liu | Jun 2021 | B2 |
| 11045346 | Argent et al. | Jun 2021 | B2 |
| D928946 | Sanchez et al. | Aug 2021 | S |
| 11179506 | Barr et al. | Nov 2021 | B2 |
| 11226376 | Yamauchi et al. | Jan 2022 | B2 |
| 11369508 | Ecklund et al. | Jun 2022 | B2 |
| 11376152 | Sanchez et al. | Jul 2022 | B2 |
| 11382786 | Sanchez et al. | Jul 2022 | B2 |
| 11382788 | Hjorth et al. | Jul 2022 | B2 |
| 11426303 | Davis et al. | Aug 2022 | B2 |
| 11529252 | Glithero et al. | Dec 2022 | B2 |
| D1010109 | Ecklund et al. | Jan 2024 | S |
| 20010037097 | Cheng et al. | Nov 2001 | A1 |
| 20010054426 | Knudson et al. | Dec 2001 | A1 |
| 20020019614 | Woon | Feb 2002 | A1 |
| 20020026161 | Grundke | Feb 2002 | A1 |
| 20020087131 | Wolff et al. | Jul 2002 | A1 |
| 20020091364 | Prabhakar | Jul 2002 | A1 |
| 20020189992 | Schmidt et al. | Dec 2002 | A1 |
| 20020193760 | Thompson | Dec 2002 | A1 |
| 20030004436 | Schmidt et al. | Jan 2003 | A1 |
| 20030032931 | Grundke et al. | Feb 2003 | A1 |
| 20030032944 | Cawood | Feb 2003 | A1 |
| 20030120178 | Heki | Jun 2003 | A1 |
| 20030157859 | Ishikawa | Aug 2003 | A1 |
| 20030181880 | Schwartz | Sep 2003 | A1 |
| 20030195484 | Harvie | Oct 2003 | A1 |
| 20030204173 | Burns et al. | Oct 2003 | A1 |
| 20030233079 | Parks et al. | Dec 2003 | A1 |
| 20040006321 | Cheng et al. | Jan 2004 | A1 |
| 20040015141 | Cheng et al. | Jan 2004 | A1 |
| 20040056122 | Male et al. | Mar 2004 | A1 |
| 20040084465 | Luburic | May 2004 | A1 |
| 20040127872 | Petryk et al. | Jul 2004 | A1 |
| 20040128749 | Scott | Jul 2004 | A1 |
| 20040143229 | Easter | Jul 2004 | A1 |
| 20040147863 | Diaz et al. | Jul 2004 | A1 |
| 20040147894 | Mizutani et al. | Jul 2004 | A1 |
| 20040158221 | Mizutani et al. | Aug 2004 | A1 |
| 20040176731 | Cheng et al. | Sep 2004 | A1 |
| 20040176746 | Forral | Sep 2004 | A1 |
| 20040191919 | Unger et al. | Sep 2004 | A1 |
| 20040207530 | Nielsen | Oct 2004 | A1 |
| 20040236292 | Tazoe et al. | Nov 2004 | A1 |
| 20040243075 | Harvie | Dec 2004 | A1 |
| 20040254547 | Okabe et al. | Dec 2004 | A1 |
| 20050010182 | Parks et al. | Jan 2005 | A1 |
| 20050033248 | Machida et al. | Feb 2005 | A1 |
| 20050065471 | Kuntz | Mar 2005 | A1 |
| 20050070861 | Okabe et al. | Mar 2005 | A1 |
| 20050070862 | Tazoe et al. | Mar 2005 | A1 |
| 20050082300 | Modrell et al. | Apr 2005 | A1 |
| 20050097662 | Leimkuhler et al. | May 2005 | A1 |
| 20050101924 | Elson et al. | May 2005 | A1 |
| 20050119630 | Harvie | Jun 2005 | A1 |
| 20050137557 | Swiecicki et al. | Jun 2005 | A1 |
| 20050154360 | Harvie | Jul 2005 | A1 |
| 20050177070 | Levinson et al. | Aug 2005 | A1 |
| 20050197639 | Mombrinie | Sep 2005 | A1 |
| 20050273920 | Marinas | Dec 2005 | A1 |
| 20050277904 | Chase et al. | Dec 2005 | A1 |
| 20050279359 | LeBlanc et al. | Dec 2005 | A1 |
| 20060004332 | Marx | Jan 2006 | A1 |
| 20060015080 | Mahnensmith | Jan 2006 | A1 |
| 20060015081 | Suzuki et al. | Jan 2006 | A1 |
| 20060016778 | Park | Jan 2006 | A1 |
| 20060069359 | Dipalma et al. | Mar 2006 | A1 |
| 20060079854 | Kay et al. | Apr 2006 | A1 |
| 20060111648 | Vermaak | May 2006 | A1 |
| 20060155214 | Wightman | Jul 2006 | A1 |
| 20060171997 | Gruenbacher et al. | Aug 2006 | A1 |
| 20060200102 | Cooper | Sep 2006 | A1 |
| 20060229575 | Boiarski | Oct 2006 | A1 |
| 20060229576 | Conway et al. | Oct 2006 | A1 |
| 20060231648 | Male et al. | Oct 2006 | A1 |
| 20060235266 | Nan | Oct 2006 | A1 |
| 20060235359 | Marland | Oct 2006 | A1 |
| 20060241553 | Harvie | Oct 2006 | A1 |
| 20060269439 | White | Nov 2006 | A1 |
| 20060277670 | Baker et al. | Dec 2006 | A1 |
| 20070006368 | Key et al. | Jan 2007 | A1 |
| 20070010797 | Nishtala et al. | Jan 2007 | A1 |
| 20070016152 | Karpowicz et al. | Jan 2007 | A1 |
| 20070038194 | Wada et al. | Feb 2007 | A1 |
| 20070055209 | Patel et al. | Mar 2007 | A1 |
| 20070073252 | Forgrave | Mar 2007 | A1 |
| 20070117880 | Elson et al. | May 2007 | A1 |
| 20070118993 | Bates | May 2007 | A1 |
| 20070135786 | Schmidt et al. | Jun 2007 | A1 |
| 20070149935 | Dirico | Jun 2007 | A1 |
| 20070191804 | Coley | Aug 2007 | A1 |
| 20070214553 | Carromba et al. | Sep 2007 | A1 |
| 20070225663 | Watt et al. | Sep 2007 | A1 |
| 20070225666 | Otto | Sep 2007 | A1 |
| 20070225668 | Otto | Sep 2007 | A1 |
| 20070266486 | Ramirez | Nov 2007 | A1 |
| 20070282309 | Bengtson et al. | Dec 2007 | A1 |
| 20080004576 | Tanaka et al. | Jan 2008 | A1 |
| 20080015526 | Reiner et al. | Jan 2008 | A1 |
| 20080015527 | House | Jan 2008 | A1 |
| 20080033386 | Okabe et al. | Feb 2008 | A1 |
| 20080041869 | Backaert | Feb 2008 | A1 |
| 20080091153 | Harvie | Apr 2008 | A1 |
| 20080091158 | Yang | Apr 2008 | A1 |
| 20080167634 | Kouta et al. | Jul 2008 | A1 |
| 20080183157 | Walters | Jul 2008 | A1 |
| 20080215031 | Belfort et al. | Sep 2008 | A1 |
| 20080234642 | Patterson et al. | Sep 2008 | A1 |
| 20080269703 | Collins et al. | Oct 2008 | A1 |
| 20080281282 | Finger et al. | Nov 2008 | A1 |
| 20080287894 | Van Den Heuvel et al. | Nov 2008 | A1 |
| 20090025717 | Pinel | Jan 2009 | A1 |
| 20090048570 | Jensen | Feb 2009 | A1 |
| 20090056003 | Ivie et al. | Mar 2009 | A1 |
| 20090069761 | Vogel | Mar 2009 | A1 |
| 20090069765 | Wortham | Mar 2009 | A1 |
| 20090192482 | Dodge et al. | Jul 2009 | A1 |
| 20090234312 | Otoole et al. | Sep 2009 | A1 |
| 20090251510 | Noro et al. | Oct 2009 | A1 |
| 20090264840 | Virginio | Oct 2009 | A1 |
| 20090270822 | Medeiros | Oct 2009 | A1 |
| 20090281510 | Fisher | Nov 2009 | A1 |
| 20100004612 | Thevenin | Jan 2010 | A1 |
| 20100058660 | Williams | Mar 2010 | A1 |
| 20100121289 | Parks et al. | May 2010 | A1 |
| 20100158168 | Murthy et al. | Jun 2010 | A1 |
| 20100160882 | Lowe | Jun 2010 | A1 |
| 20100174250 | Hu et al. | Jul 2010 | A1 |
| 20100185168 | Graauw et al. | Jul 2010 | A1 |
| 20100198172 | Wada et al. | Aug 2010 | A1 |
| 20100211032 | Tsai et al. | Aug 2010 | A1 |
| 20100234820 | Tsai et al. | Sep 2010 | A1 |
| 20100241104 | Gilbert | Sep 2010 | A1 |
| 20100263113 | Shelton et al. | Oct 2010 | A1 |
| 20100310845 | Bond et al. | Dec 2010 | A1 |
| 20110028920 | Johannison | Feb 2011 | A1 |
| 20110028922 | Kay et al. | Feb 2011 | A1 |
| 20110034889 | Smith | Feb 2011 | A1 |
| 20110036837 | Shang | Feb 2011 | A1 |
| 20110040267 | Wada et al. | Feb 2011 | A1 |
| 20110040271 | Rogers et al. | Feb 2011 | A1 |
| 20110054426 | Stewart et al. | Mar 2011 | A1 |
| 20110060299 | Wada et al. | Mar 2011 | A1 |
| 20110060300 | Weig et al. | Mar 2011 | A1 |
| 20110077495 | Gilbert | Mar 2011 | A1 |
| 20110077606 | Wilcox et al. | Mar 2011 | A1 |
| 20110087337 | Forsell | Apr 2011 | A1 |
| 20110145993 | Rader et al. | Jun 2011 | A1 |
| 20110152802 | DiCamillo et al. | Jun 2011 | A1 |
| 20110164147 | Takahashi et al. | Jul 2011 | A1 |
| 20110172620 | Khambatta | Jul 2011 | A1 |
| 20110172625 | Wada et al. | Jul 2011 | A1 |
| 20110202024 | Cozzens | Aug 2011 | A1 |
| 20110238023 | Slayton | Sep 2011 | A1 |
| 20110240648 | Tucker | Oct 2011 | A1 |
| 20110251572 | Nishtala et al. | Oct 2011 | A1 |
| 20110265889 | Tanaka et al. | Nov 2011 | A1 |
| 20110276020 | Mitsui | Nov 2011 | A1 |
| 20120035577 | Tomes et al. | Feb 2012 | A1 |
| 20120041400 | Christensen | Feb 2012 | A1 |
| 20120059328 | Dikeman et al. | Mar 2012 | A1 |
| 20120066825 | Birbara et al. | Mar 2012 | A1 |
| 20120103347 | Wheaton et al. | May 2012 | A1 |
| 20120137420 | Gordon et al. | Jun 2012 | A1 |
| 20120165768 | Sekiyama et al. | Jun 2012 | A1 |
| 20120165786 | Chappa et al. | Jun 2012 | A1 |
| 20120210503 | Anzivino et al. | Aug 2012 | A1 |
| 20120233761 | Huang | Sep 2012 | A1 |
| 20120245541 | Suzuki et al. | Sep 2012 | A1 |
| 20120245542 | Suzuki et al. | Sep 2012 | A1 |
| 20120245547 | Wilcox et al. | Sep 2012 | A1 |
| 20120253303 | Suzuki et al. | Oct 2012 | A1 |
| 20120271259 | Ulert | Oct 2012 | A1 |
| 20120296305 | Barraza Khaled et al. | Nov 2012 | A1 |
| 20120316522 | Carter et al. | Dec 2012 | A1 |
| 20120330256 | Wilcox et al. | Dec 2012 | A1 |
| 20130006206 | Wada et al. | Jan 2013 | A1 |
| 20130045651 | Esteves et al. | Feb 2013 | A1 |
| 20130053804 | Soerensen et al. | Feb 2013 | A1 |
| 20130096523 | Chang et al. | Apr 2013 | A1 |
| 20130150813 | Gordon et al. | Jun 2013 | A1 |
| 20130245496 | Wells et al. | Sep 2013 | A1 |
| 20130245586 | Jha | Sep 2013 | A1 |
| 20130292537 | Dirico | Nov 2013 | A1 |
| 20140005647 | Shuffler et al. | Jan 2014 | A1 |
| 20140031774 | Bengtson | Jan 2014 | A1 |
| 20140157499 | Suzuki et al. | Jun 2014 | A1 |
| 20140171889 | Hopman et al. | Jun 2014 | A1 |
| 20140182051 | Tanimoto et al. | Jul 2014 | A1 |
| 20140196189 | Lee et al. | Jul 2014 | A1 |
| 20140303582 | Wright et al. | Oct 2014 | A1 |
| 20140316381 | Reglin | Oct 2014 | A1 |
| 20140325746 | Block | Nov 2014 | A1 |
| 20140348139 | Gomez Martinez | Nov 2014 | A1 |
| 20140352050 | Yao et al. | Dec 2014 | A1 |
| 20140371628 | Desai | Dec 2014 | A1 |
| 20150045757 | Lee et al. | Feb 2015 | A1 |
| 20150047114 | Ramirez | Feb 2015 | A1 |
| 20150048089 | Robertson | Feb 2015 | A1 |
| 20150135423 | Sharpe et al. | May 2015 | A1 |
| 20150157300 | Ealovega et al. | Jun 2015 | A1 |
| 20150209194 | Heyman | Jul 2015 | A1 |
| 20150290425 | Macy et al. | Oct 2015 | A1 |
| 20150320583 | Harvie | Nov 2015 | A1 |
| 20150329255 | Rzepecki | Nov 2015 | A1 |
| 20150342799 | Michiels et al. | Dec 2015 | A1 |
| 20150359660 | Harvie | Dec 2015 | A1 |
| 20150366699 | Nelson | Dec 2015 | A1 |
| 20160029998 | Brister et al. | Feb 2016 | A1 |
| 20160030228 | Jones | Feb 2016 | A1 |
| 20160038356 | Yao et al. | Feb 2016 | A1 |
| 20160058322 | Brister et al. | Mar 2016 | A1 |
| 20160060001 | Wada et al. | Mar 2016 | A1 |
| 20160100976 | Conway et al. | Apr 2016 | A1 |
| 20160106604 | Timm | Apr 2016 | A1 |
| 20160113809 | Kim | Apr 2016 | A1 |
| 20160183689 | Miner | Jun 2016 | A1 |
| 20160256022 | Le | Sep 2016 | A1 |
| 20160270982 | Raycheck et al. | Sep 2016 | A1 |
| 20160278662 | Brister et al. | Sep 2016 | A1 |
| 20160357400 | Penha et al. | Dec 2016 | A1 |
| 20160366699 | Zhang et al. | Dec 2016 | A1 |
| 20160367226 | Newton et al. | Dec 2016 | A1 |
| 20160367411 | Justiz et al. | Dec 2016 | A1 |
| 20160374848 | Sanchez et al. | Dec 2016 | A1 |
| 20170007438 | Harvie | Jan 2017 | A1 |
| 20170014560 | Minskoff et al. | Jan 2017 | A1 |
| 20170100276 | Joh | Apr 2017 | A1 |
| 20170128638 | Giezendanner et al. | May 2017 | A1 |
| 20170143534 | Sanchez | May 2017 | A1 |
| 20170165405 | Muser et al. | Jun 2017 | A1 |
| 20170189225 | Voorhees et al. | Jul 2017 | A1 |
| 20170202692 | Laniado | Jul 2017 | A1 |
| 20170216081 | Accosta | Aug 2017 | A1 |
| 20170246026 | Laniado | Aug 2017 | A1 |
| 20170252014 | Siller Gonzalez et al. | Sep 2017 | A1 |
| 20170252202 | Sanchez et al. | Sep 2017 | A9 |
| 20170266031 | Sanchez et al. | Sep 2017 | A1 |
| 20170266658 | Bruno et al. | Sep 2017 | A1 |
| 20170281399 | Vanmiddendorp et al. | Oct 2017 | A1 |
| 20170312116 | Laniado | Nov 2017 | A1 |
| 20170325788 | Ealovega et al. | Nov 2017 | A1 |
| 20170333244 | Laniado | Nov 2017 | A1 |
| 20170042748 | Griffin | Dec 2017 | A1 |
| 20170348139 | Newton et al. | Dec 2017 | A1 |
| 20170354532 | Holt | Dec 2017 | A1 |
| 20170367873 | Grannum | Dec 2017 | A1 |
| 20180002075 | Lee | Jan 2018 | A1 |
| 20180008451 | Stroebech | Jan 2018 | A1 |
| 20180008804 | Laniado | Jan 2018 | A1 |
| 20180021218 | Brosch et al. | Jan 2018 | A1 |
| 20180028349 | Newton et al. | Feb 2018 | A1 |
| 20180037384 | Archeny et al. | Feb 2018 | A1 |
| 20180049910 | Newton | Feb 2018 | A1 |
| 20180064572 | Wiltshire | Mar 2018 | A1 |
| 20180104131 | Killian | Apr 2018 | A1 |
| 20180127187 | Sewell | May 2018 | A1 |
| 20180193215 | Davies et al. | Jul 2018 | A1 |
| 20180200101 | Su | Jul 2018 | A1 |
| 20180228642 | Davis et al. | Aug 2018 | A1 |
| 20180256384 | Kasirye | Sep 2018 | A1 |
| 20180271694 | Fernandez et al. | Sep 2018 | A1 |
| 20180317892 | Catlin | Nov 2018 | A1 |
| 20190001030 | Braga et al. | Jan 2019 | A1 |
| 20190021899 | Vlet | Jan 2019 | A1 |
| 20190038451 | Harvie | Feb 2019 | A1 |
| 20190046102 | Kushnir et al. | Feb 2019 | A1 |
| 20190100362 | Meyers et al. | Apr 2019 | A1 |
| 20190133814 | Tammen et al. | May 2019 | A1 |
| 20190142624 | Sanchez et al. | May 2019 | A1 |
| 20190224036 | Sanchez et al. | Jul 2019 | A1 |
| 20190247222 | Ecklund et al. | Aug 2019 | A1 |
| 20190247223 | Brun et al. | Aug 2019 | A1 |
| 20190282391 | Johannes et al. | Sep 2019 | A1 |
| 20190314189 | Acosta | Oct 2019 | A1 |
| 20190314190 | Sanchez et al. | Oct 2019 | A1 |
| 20190321587 | McMenamin et al. | Oct 2019 | A1 |
| 20190344934 | Faerber et al. | Nov 2019 | A1 |
| 20190365307 | Laing et al. | Dec 2019 | A1 |
| 20190365561 | Newton et al. | Dec 2019 | A1 |
| 20200008985 | Nguyen et al. | Jan 2020 | A1 |
| 20200030595 | Boukidjian et al. | Jan 2020 | A1 |
| 20200046544 | Godinez et al. | Feb 2020 | A1 |
| 20200055638 | Lau et al. | Feb 2020 | A1 |
| 20200070392 | Huber et al. | Mar 2020 | A1 |
| 20200085609 | Schelch et al. | Mar 2020 | A1 |
| 20200085610 | Cohn et al. | Mar 2020 | A1 |
| 20200086090 | Von Weymarn-Schärli et al. | Mar 2020 | A1 |
| 20200129322 | Leuckel | Apr 2020 | A1 |
| 20200171217 | Braga et al. | Jun 2020 | A9 |
| 20200229964 | Staali et al. | Jul 2020 | A1 |
| 20200231343 | Freedman et al. | Jul 2020 | A1 |
| 20200232841 | Satish et al. | Jul 2020 | A1 |
| 20200246172 | Ho | Aug 2020 | A1 |
| 20200255189 | Liu | Aug 2020 | A1 |
| 20200261280 | Heyman | Aug 2020 | A1 |
| 20200276046 | Staali et al. | Sep 2020 | A1 |
| 20200306075 | Newton et al. | Oct 2020 | A1 |
| 20200315838 | Eckert | Oct 2020 | A1 |
| 20200331672 | Bertram et al. | Oct 2020 | A1 |
| 20200345332 | Duval | Nov 2020 | A1 |
| 20200353135 | Gregory et al. | Nov 2020 | A1 |
| 20200367677 | Silsby et al. | Nov 2020 | A1 |
| 20200369444 | Silsby et al. | Nov 2020 | A1 |
| 20200375781 | Staali et al. | Dec 2020 | A1 |
| 20200385179 | McCourt | Dec 2020 | A1 |
| 20200390591 | Glithero et al. | Dec 2020 | A1 |
| 20200390592 | Merrill | Dec 2020 | A1 |
| 20200405521 | Glasroe | Dec 2020 | A1 |
| 20210008771 | Huber et al. | Jan 2021 | A1 |
| 20210009323 | Markarian et al. | Jan 2021 | A1 |
| 20210059853 | Davis et al. | Mar 2021 | A1 |
| 20210061523 | Bytheway | Mar 2021 | A1 |
| 20210069005 | Sanchez et al. | Mar 2021 | A1 |
| 20210069008 | Blabas et al. | Mar 2021 | A1 |
| 20210069009 | Im | Mar 2021 | A1 |
| 20210077993 | Nazareth et al. | Mar 2021 | A1 |
| 20210113749 | Radl et al. | Apr 2021 | A1 |
| 20210121318 | Pinlac | Apr 2021 | A1 |
| 20210137724 | Ecklund et al. | May 2021 | A1 |
| 20210138190 | Erbey et al. | May 2021 | A1 |
| 20210154055 | Villarreal | May 2021 | A1 |
| 20210170079 | Radl et al. | Jun 2021 | A1 |
| 20210178390 | Oueslati et al. | Jun 2021 | A1 |
| 20210220162 | Jamison | Jul 2021 | A1 |
| 20210220163 | Mayrand | Jul 2021 | A1 |
| 20210228400 | Glithero | Jul 2021 | A1 |
| 20210228401 | Becker et al. | Jul 2021 | A1 |
| 20210228795 | Hughett et al. | Jul 2021 | A1 |
| 20210229877 | Ragias et al. | Jul 2021 | A1 |
| 20210236323 | Austermann et al. | Aug 2021 | A1 |
| 20210267787 | Nazemi | Sep 2021 | A1 |
| 20210275343 | Sanchez et al. | Sep 2021 | A1 |
| 20210315727 | Jiang | Oct 2021 | A1 |
| 20210353450 | Sharma et al. | Nov 2021 | A1 |
| 20210361469 | Liu et al. | Nov 2021 | A1 |
| 20210369495 | Cheng et al. | Dec 2021 | A1 |
| 20210386925 | Hartwell et al. | Dec 2021 | A1 |
| 20210393433 | Godinez et al. | Dec 2021 | A1 |
| 20220023091 | Ecklund et al. | Jan 2022 | A1 |
| 20220047410 | Walthall | Feb 2022 | A1 |
| 20220062027 | Mitchell et al. | Mar 2022 | A1 |
| 20220062028 | Mitchell et al. | Mar 2022 | A1 |
| 20220062029 | Johannes et al. | Mar 2022 | A1 |
| 20220066825 | Saraf et al. | Mar 2022 | A1 |
| 20220071811 | Cheng et al. | Mar 2022 | A1 |
| 20220071826 | Kulkarni et al. | Mar 2022 | A1 |
| 20220104965 | Vaninetti et al. | Apr 2022 | A1 |
| 20220104981 | Jones | Apr 2022 | A1 |
| 20220117774 | Meyer et al. | Apr 2022 | A1 |
| 20220117775 | Jones et al. | Apr 2022 | A1 |
| 20220133524 | Davis | May 2022 | A1 |
| 20220151817 | Mann | May 2022 | A1 |
| 20220160949 | Simiele et al. | May 2022 | A1 |
| 20220193312 | Lee et al. | Jun 2022 | A1 |
| 20220211536 | Johannes et al. | Jul 2022 | A1 |
| 20220218510 | Metzger et al. | Jul 2022 | A1 |
| 20220229053 | Levin et al. | Jul 2022 | A1 |
| 20220248836 | Cagle et al. | Aug 2022 | A1 |
| 20220257407 | Johannes et al. | Aug 2022 | A1 |
| 20220265462 | Alder et al. | Aug 2022 | A1 |
| 20220273482 | Johannes et al. | Sep 2022 | A1 |
| 20220280357 | Jagannathan et al. | Sep 2022 | A1 |
| 20220313222 | Austermann et al. | Oct 2022 | A1 |
| 20220313474 | Kriscovich et al. | Oct 2022 | A1 |
| 20220354685 | Davis et al. | Nov 2022 | A1 |
| 20220370231 | Wang et al. | Nov 2022 | A1 |
| 20220370234 | Hughett et al. | Nov 2022 | A1 |
| 20220370235 | Johannes et al. | Nov 2022 | A1 |
| 20220370237 | Parmar et al. | Nov 2022 | A1 |
| 20220387001 | Askenazi et al. | Dec 2022 | A1 |
| 20220395391 | Saunders et al. | Dec 2022 | A1 |
| 20230018845 | Lee | Jan 2023 | A1 |
| 20230020563 | Sharma et al. | Jan 2023 | A1 |
| 20230031640 | Hughett et al. | Feb 2023 | A1 |
| 20230037159 | Brennan et al. | Feb 2023 | A1 |
| 20230062944 | Vollenberg et al. | Mar 2023 | A1 |
| 20230062994 | Ecklund et al. | Mar 2023 | A1 |
| 20230089032 | Hughett et al. | Mar 2023 | A1 |
| 20230105001 | Whittome et al. | Apr 2023 | A1 |
| 20230138269 | Abdelal et al. | May 2023 | A1 |
| 20230145365 | Martin et al. | May 2023 | A1 |
| 20230277362 | Davis et al. | Sep 2023 | A1 |
| 20230404791 | Ecklund et al. | Dec 2023 | A1 |
| Number | Date | Country |
|---|---|---|
| 2018216821 | Aug 2019 | AU |
| 2165286 | Sep 1999 | CA |
| 2354132 | Jun 2000 | CA |
| 2488867 | Aug 2007 | CA |
| 3050918 | Aug 2018 | CA |
| 3098571 | Nov 2019 | CA |
| 3098571 | Nov 2019 | CA |
| 2269203 | Dec 1997 | CN |
| 1332620 | Jan 2002 | CN |
| 1533755 | Oct 2004 | CN |
| 1602825 | Apr 2005 | CN |
| 1720888 | Jan 2006 | CN |
| 2936204 | Aug 2007 | CN |
| 101262836 | Sep 2008 | CN |
| 101522148 | Sep 2009 | CN |
| 102159159 | Aug 2011 | CN |
| 202184840 | Apr 2012 | CN |
| 102481441 | May 2012 | CN |
| 202463712 | Oct 2012 | CN |
| 103533968 | Jan 2014 | CN |
| 103717180 | Apr 2014 | CN |
| 204562697 | Aug 2015 | CN |
| 105411783 | Mar 2016 | CN |
| 105451693 | Mar 2016 | CN |
| 105534632 | May 2016 | CN |
| 205849719 | Jan 2017 | CN |
| 106726089 | May 2017 | CN |
| 107847384 | Mar 2018 | CN |
| 107920912 | Apr 2018 | CN |
| 209285902 | Aug 2019 | CN |
| 110381883 | Oct 2019 | CN |
| 211198839 | Aug 2020 | CN |
| 112566550 | Mar 2021 | CN |
| 112603184 | Apr 2021 | CN |
| 114007493 | Feb 2022 | CN |
| 114375187 | Apr 2022 | CN |
| 116096332 | May 2023 | CN |
| 1516466 | Jun 1969 | DE |
| 2721330 | Nov 1977 | DE |
| 2742298 | Mar 1978 | DE |
| 94075549 | May 1995 | DE |
| 4443710 | Jun 1995 | DE |
| 4416094 | Nov 1995 | DE |
| 4236097 | Oct 1996 | DE |
| 19619597 | Nov 1997 | DE |
| 102005037762 | Sep 2006 | DE |
| 102011103783 | Dec 2012 | DE |
| 202015104597 | Jul 2016 | DE |
| 9600118 | Nov 1996 | DK |
| 0032138 | Jul 1981 | EP |
| 0066070 | Dec 1982 | EP |
| 0274753 | Jul 1988 | EP |
| 0119143 | Nov 1988 | EP |
| 0483592 | May 1992 | EP |
| 0610638 | Aug 1994 | EP |
| 0613355 | Sep 1994 | EP |
| 0613355 | Jan 1997 | EP |
| 0787472 | Aug 1997 | EP |
| 0966936 | Dec 1999 | EP |
| 0987293 | Mar 2000 | EP |
| 1063953 | Jan 2001 | EP |
| 0653928 | Oct 2002 | EP |
| 1332738 | Aug 2003 | EP |
| 1382318 | Jan 2004 | EP |
| 1089684 | Oct 2004 | EP |
| 1616542 | Jan 2006 | EP |
| 1382318 | May 2006 | EP |
| 1063953 | Jan 2007 | EP |
| 1872752 | Jan 2008 | EP |
| 2180907 | May 2010 | EP |
| 2380532 | Oct 2011 | EP |
| 2389908 | Nov 2011 | EP |
| 2601916 | Jun 2013 | EP |
| 2676643 | Dec 2013 | EP |
| 2997950 | Mar 2016 | EP |
| 2879534 | Mar 2017 | EP |
| 3424471 | Jan 2019 | EP |
| 3169292 | Nov 2019 | EP |
| 3753492 | Dec 2020 | EP |
| 3788992 | Mar 2021 | EP |
| 3576689 | Mar 2022 | EP |
| 3752110 | Mar 2022 | EP |
| 4025163 | Jul 2022 | EP |
| 3463180 | Mar 2023 | EP |
| 1011517 | Dec 1965 | GB |
| 1467144 | Mar 1977 | GB |
| 2106395 | Apr 1983 | GB |
| 2106784 | Apr 1983 | GB |
| 2148126 | May 1985 | GB |
| 2171315 | Aug 1986 | GB |
| 2148126 | Jul 1987 | GB |
| 2191095 | Dec 1987 | GB |
| 2199750 | Jul 1988 | GB |
| 2260907 | May 1993 | GB |
| 2462267 | Feb 2010 | GB |
| 2469496 | Oct 2010 | GB |
| 2490327 | Oct 2012 | GB |
| 2507318 | Apr 2014 | GB |
| 2612752 | May 2023 | GB |
| 201800009129 | Apr 2020 | IT |
| S5410596 | Jan 1979 | JP |
| S5410596 | May 1979 | JP |
| S55155618 | Dec 1980 | JP |
| S5888596 | Jun 1983 | JP |
| S63107780 | Jul 1988 | JP |
| H0267530 | Mar 1990 | JP |
| H02103871 | Apr 1990 | JP |
| H02131422 | May 1990 | JP |
| H02131422 | Nov 1990 | JP |
| H0460220 | Feb 1992 | JP |
| H05123349 | May 1993 | JP |
| H05123350 | May 1993 | JP |
| 3087938 | Oct 1995 | JP |
| H085630 | Jan 1996 | JP |
| H1040141 | Feb 1998 | JP |
| H10225430 | Aug 1998 | JP |
| H11113946 | Apr 1999 | JP |
| H11290365 | Oct 1999 | JP |
| 2000116690 | Apr 2000 | JP |
| 2000185068 | Jul 2000 | JP |
| 2001054531 | Feb 2001 | JP |
| 2001070331 | Mar 2001 | JP |
| 2001224616 | Aug 2001 | JP |
| 2001276107 | Oct 2001 | JP |
| 2001276108 | Oct 2001 | JP |
| 2002028173 | Jan 2002 | JP |
| 2003505152 | Feb 2003 | JP |
| 2003180722 | Jul 2003 | JP |
| 2004130056 | Apr 2004 | JP |
| 2004267530 | Sep 2004 | JP |
| 2005066011 | Mar 2005 | JP |
| 2005066325 | Mar 2005 | JP |
| 2005518237 | Jun 2005 | JP |
| 3749097 | Dec 2005 | JP |
| 2006026108 | Feb 2006 | JP |
| 3123547 | Jun 2006 | JP |
| 2006136492 | Jun 2006 | JP |
| 2006204868 | Aug 2006 | JP |
| 2007044494 | Feb 2007 | JP |
| 3132659 | May 2007 | JP |
| 4039641 | Nov 2007 | JP |
| 2009509570 | Mar 2009 | JP |
| 2010081981 | Apr 2010 | JP |
| 4640772 | Dec 2010 | JP |
| 2010536439 | Dec 2010 | JP |
| 4747166 | May 2011 | JP |
| 2011087823 | May 2011 | JP |
| 4801218 | Aug 2011 | JP |
| 2011218130 | Nov 2011 | JP |
| 2011224070 | Nov 2011 | JP |
| 2012523869 | Oct 2012 | JP |
| 2013238608 | Nov 2013 | JP |
| 2014521960 | Aug 2014 | JP |
| 2015092945 | May 2015 | JP |
| 3198994 | Jul 2015 | JP |
| 2019525811 | Sep 2019 | JP |
| 2021120686 | Aug 2021 | JP |
| 2021522009 | Aug 2021 | JP |
| 7129493 | Aug 2022 | JP |
| 2023532132 | Jul 2023 | JP |
| 200290061 | Sep 2002 | KR |
| 20030047451 | Jun 2003 | KR |
| 20140039485 | Apr 2014 | KR |
| 101432639 | Aug 2014 | KR |
| 20180106659 | Oct 2018 | KR |
| 20180108774 | Oct 2018 | KR |
| 2068717 | Jun 2013 | PT |
| 8101957 | Jul 1981 | WO |
| 8804558 | Jun 1988 | WO |
| 9104714 | Apr 1991 | WO |
| 9104714 | Jun 1991 | WO |
| 9220299 | Feb 1993 | WO |
| 9307839 | Apr 1993 | WO |
| 9309736 | May 1993 | WO |
| 9309736 | Jun 1993 | WO |
| 9514448 | Jun 1995 | WO |
| 9600096 | Jan 1996 | WO |
| 9634636 | Nov 1996 | WO |
| 9817211 | Apr 1998 | WO |
| 9830336 | Jul 1998 | WO |
| 0000112 | Jan 2000 | WO |
| 0000113 | Jan 2000 | WO |
| 0025651 | May 2000 | WO |
| 0033773 | Jun 2000 | WO |
| 0057784 | Oct 2000 | WO |
| 0069377 | Nov 2000 | WO |
| 0145618 | Jun 2001 | WO |
| 0145621 | Jun 2001 | WO |
| 02094160 | Nov 2002 | WO |
| 03013967 | Feb 2003 | WO |
| 03024824 | Mar 2003 | WO |
| 03055423 | Jul 2003 | WO |
| 03071931 | Sep 2003 | WO |
| 03079942 | Oct 2003 | WO |
| 03071931 | Feb 2004 | WO |
| 2004019836 | Mar 2004 | WO |
| 2004024046 | Mar 2004 | WO |
| 2005051252 | Jun 2005 | WO |
| 2005074571 | Sep 2005 | WO |
| 2005089687 | Sep 2005 | WO |
| 2005107661 | Nov 2005 | WO |
| 2006021220 | Mar 2006 | WO |
| 2006037140 | Apr 2006 | WO |
| 2007005851 | Jan 2007 | WO |
| 2007007845 | Jan 2007 | WO |
| 2007042823 | Apr 2007 | WO |
| 2007055651 | May 2007 | WO |
| 2006098950 | Nov 2007 | WO |
| 2007128156 | Feb 2008 | WO |
| 2008026106 | Mar 2008 | WO |
| 2008078117 | Jul 2008 | WO |
| 2008104019 | Sep 2008 | WO |
| 2008141471 | Nov 2008 | WO |
| 2009004368 | Jan 2009 | WO |
| 2009004369 | Jan 2009 | WO |
| 2009052496 | Apr 2009 | WO |
| 2009052502 | Apr 2009 | WO |
| 2009007702 | Jul 2009 | WO |
| 2009101738 | Aug 2009 | WO |
| 2010058192 | May 2010 | WO |
| 2010030122 | Jul 2010 | WO |
| 2010101915 | Jan 2011 | WO |
| 2011018132 | Feb 2011 | WO |
| 2011018133 | Feb 2011 | WO |
| 2011024864 | Mar 2011 | WO |
| 2011054118 | May 2011 | WO |
| 2011079132 | Jun 2011 | WO |
| 2011107972 | Sep 2011 | WO |
| 2011108972 | Sep 2011 | WO |
| 2011117292 | Sep 2011 | WO |
| 2011123219 | Oct 2011 | WO |
| 2011132043 | Oct 2011 | WO |
| 2012012908 | Feb 2012 | WO |
| 2012065274 | May 2012 | WO |
| 2012097462 | Jul 2012 | WO |
| 2012098796 | Jul 2012 | WO |
| 2012101288 | Aug 2012 | WO |
| 2012175916 | Dec 2012 | WO |
| 2013018435 | Feb 2013 | WO |
| 2013033429 | Mar 2013 | WO |
| 2013055434 | Apr 2013 | WO |
| WO-2013082397 | Jun 2013 | WO |
| 2013103291 | Jul 2013 | WO |
| 2013131109 | Sep 2013 | WO |
| 2013167478 | Nov 2013 | WO |
| 2013177716 | Dec 2013 | WO |
| 2014041534 | Mar 2014 | WO |
| 2014046420 | Mar 2014 | WO |
| 2014118518 | Aug 2014 | WO |
| 2014160852 | Oct 2014 | WO |
| 2015023599 | Feb 2015 | WO |
| 2015052348 | Apr 2015 | WO |
| 2015068384 | May 2015 | WO |
| 2015169403 | Nov 2015 | WO |
| 2015170307 | Nov 2015 | WO |
| 2015197462 | Dec 2015 | WO |
| 2016051385 | Apr 2016 | WO |
| 2016055989 | Apr 2016 | WO |
| 2016071894 | May 2016 | WO |
| 2016103242 | Jun 2016 | WO |
| 2016116915 | Jul 2016 | WO |
| 2016124203 | Aug 2016 | WO |
| 2016139448 | Sep 2016 | WO |
| 2016166562 | Oct 2016 | WO |
| 2016167535 | Oct 2016 | WO |
| 2016191574 | Dec 2016 | WO |
| 2016200088 | Dec 2016 | WO |
| 2016200361 | Dec 2016 | WO |
| 2016204731 | Dec 2016 | WO |
| WO-2017075226 | May 2017 | WO |
| 2017152198 | Sep 2017 | WO |
| 2017153357 | Sep 2017 | WO |
| 2017162559 | Sep 2017 | WO |
| 2017205446 | Nov 2017 | WO |
| 2017209779 | Dec 2017 | WO |
| 2017210524 | Dec 2017 | WO |
| 2018022414 | Feb 2018 | WO |
| 2018044781 | Mar 2018 | WO |
| 2018056953 | Mar 2018 | WO |
| 2018090550 | May 2018 | WO |
| 2018138513 | Aug 2018 | WO |
| 2018144318 | Aug 2018 | WO |
| 2018144463 | Aug 2018 | WO |
| 2018150263 | Aug 2018 | WO |
| 2018150268 | Aug 2018 | WO |
| 2018152156 | Aug 2018 | WO |
| 2018183791 | Oct 2018 | WO |
| 2018150267 | Nov 2018 | WO |
| 2018235026 | Dec 2018 | WO |
| 2018235065 | Dec 2018 | WO |
| 2019004404 | Jan 2019 | WO |
| 2019065541 | Apr 2019 | WO |
| 2019096845 | May 2019 | WO |
| 2019150385 | Aug 2019 | WO |
| 2019161094 | Aug 2019 | WO |
| 2019188566 | Oct 2019 | WO |
| 2019190593 | Oct 2019 | WO |
| 2019212949 | Nov 2019 | WO |
| 2019212950 | Nov 2019 | WO |
| 2019212951 | Nov 2019 | WO |
| 2019212952 | Nov 2019 | WO |
| 2019212954 | Nov 2019 | WO |
| 2019212955 | Nov 2019 | WO |
| 2019212956 | Nov 2019 | WO |
| 2019214787 | Nov 2019 | WO |
| 2019214788 | Nov 2019 | WO |
| 2019226826 | Nov 2019 | WO |
| 2019239433 | Dec 2019 | WO |
| 2020000994 | Jan 2020 | WO |
| 2020020618 | Jan 2020 | WO |
| 2020038822 | Feb 2020 | WO |
| 2020088409 | May 2020 | WO |
| 2020049394 | Jun 2020 | WO |
| 2020120657 | Jun 2020 | WO |
| 2020152575 | Jul 2020 | WO |
| 2020182923 | Sep 2020 | WO |
| 2020204967 | Oct 2020 | WO |
| 2020209898 | Oct 2020 | WO |
| 2020242790 | Dec 2020 | WO |
| 2020251893 | Dec 2020 | WO |
| 2020256865 | Dec 2020 | WO |
| 2021007144 | Jan 2021 | WO |
| 2021007345 | Jan 2021 | WO |
| 2021010844 | Jan 2021 | WO |
| 2021016026 | Jan 2021 | WO |
| 2021016300 | Jan 2021 | WO |
| 2021025919 | Feb 2021 | WO |
| 2021034886 | Feb 2021 | WO |
| 2021041123 | Mar 2021 | WO |
| 2021086868 | May 2021 | WO |
| 2021094352 | May 2021 | WO |
| 2021094639 | May 2021 | WO |
| 2021102296 | May 2021 | WO |
| 2021138411 | Jul 2021 | WO |
| 2021138414 | Jul 2021 | WO |
| 2021155206 | Aug 2021 | WO |
| 2021173436 | Sep 2021 | WO |
| 2021195384 | Sep 2021 | WO |
| 2021207621 | Oct 2021 | WO |
| 2021211568 | Oct 2021 | WO |
| 2021216419 | Oct 2021 | WO |
| 2021216422 | Oct 2021 | WO |
| 2021231532 | Nov 2021 | WO |
| 2021247523 | Dec 2021 | WO |
| 2021257202 | Dec 2021 | WO |
| 2022006256 | Jan 2022 | WO |
| 2022031943 | Feb 2022 | WO |
| 2022035745 | Feb 2022 | WO |
| 2022076427 | Apr 2022 | WO |
| 2022086898 | Apr 2022 | WO |
| 2022098536 | May 2022 | WO |
| 2022125685 | Jun 2022 | WO |
| 2022140545 | Jun 2022 | WO |
| 2022150360 | Jul 2022 | WO |
| 2022150463 | Jul 2022 | WO |
| 2022159392 | Jul 2022 | WO |
| 2022170182 | Aug 2022 | WO |
| 2022182385 | Sep 2022 | WO |
| 2022192188 | Sep 2022 | WO |
| 2022192347 | Sep 2022 | WO |
| 2023014639 | Feb 2023 | WO |
| 2023014641 | Feb 2023 | WO |
| 2023034453 | Mar 2023 | WO |
| 2023038945 | Mar 2023 | WO |
| 2023038950 | Mar 2023 | WO |
| 2023049175 | Mar 2023 | WO |
| 2023086394 | May 2023 | WO |
| 2023191764 | Oct 2023 | WO |
| Entry |
|---|
| US 9,908,683 B2, 03/2018, Sandhausen et al. (withdrawn) |
| Advisory Action for U.S. Appl. No. 14/722,613 dated Mar. 4, 2019. |
| Advisory Action for U.S. Appl. No. 14/952,591 dated Jun. 1, 2018. |
| Advisory Action for U.S. Appl. No. 15/238,427 dated Apr. 10, 2019. |
| Corrected International Search Report and Written Opinion for International Application No. PCT/US2017/043025 dated Jan. 11, 2018. |
| Corrected Notice of Allowability for U.S. Appl. No. 15/221,106 dated Jul. 2, 2019. |
| Corrected Notice of Allowability for U.S. Appl. No. 15/612,325 dated Mar. 17, 2021. |
| Final Office Action for U.S. Appl. No. 14/722,613 dated Nov. 29, 2018. |
| Final Office Action for U.S. Appl. No. 14/947,759 dated Apr. 8, 2016. |
| Final Office Action for U.S. Appl. No. 14/952,591 dated Feb. 23, 2018. |
| Final Office Action for U.S. Appl. No. 14/952,591 dated Nov. 1, 2019. |
| Final Office Action for U.S. Appl. No. 14/952,591 dated Nov. 27, 2020. |
| Final Office Action for U.S. Appl. No. 15/171,968 dated Feb. 14, 2020. |
| Final Office Action for U.S. Appl. No. 15/171,968 dated Mar. 19, 2019. |
| Final Office Action for U.S. Appl. No. 15/221,106 dated Jan. 23, 2019. |
| Final Office Action for U.S. Appl. No. 15/238,427 dated Jan. 2, 2019. |
| Final Office Action for U.S. Appl. No. 15/260,103 dated Feb. 14, 2019. |
| Final Office Action for U.S. Appl. No. 15/612,325 dated Sep. 17, 2020. |
| Final Office Action for U.S. Appl. No. 16/899,956 dated Apr. 19, 2021. |
| Final Office Action for U.S. Appl. No. 16/904,868 dated Mar. 26, 2021. |
| Final Office Action for U.S. Appl. No. 16/905,400 dated Apr. 6, 2021. |
| Final Office Action for U.S. Appl. No. 29/624,661 dated Feb. 18, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2016/049274 dated Dec. 1, 2016. |
| International Search Report and Written Opinion from International Application No. PCT/US2017/035625 dated Aug. 15, 2017. |
| International Search Report and Written Opinion from International Application No. PCT/US2017/043025 dated Oct. 18, 2017. |
| International Search Report and Written Opinion from International Application No. PCT/US2018/015968 dated Apr. 6, 2018. |
| International Search Report and Written Opinion from International Application No. PCT/US2019/029608 dated Sep. 3, 2019. |
| International Search Report and Written Opinion from International Application No. PCT/US2019/029609 dated Sep. 3, 2019. |
| International Search Report and Written Opinion from International Application No. PCT/US2019/029610 dated Sep. 3, 2019. |
| International Search Report and Written Opinion from International Application No. PCT/US2019/029611 dated Jul. 3, 2019. |
| International Search Report and Written Opinion from International Application No. PCT/US2019/029613 dated Jul. 3, 2019. |
| International Search Report and Written Opinion from International Application No. PCT/US2019/029614 dated Sep. 26, 2019. |
| International Search Report and Written Opinion from International Application No. PCT/US2019/029616 dated Aug. 30, 2019. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/023572 dated Jul. 6, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/033064 dated Aug. 31, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/033122 dated Aug. 31, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/040860 dated Oct. 2, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/041242 dated Nov. 17, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/041249 dated Oct. 2, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/042262 dated Oct. 14, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/043059 dated Oct. 6, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/044024 dated Nov. 12, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/046914 dated Dec. 1, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/055680 dated Dec. 15, 2020. |
| Issue Notification for U.S. Appl. No. 15/171,968 dated Mar. 3, 2021. |
| Issue Notification for U.S. Appl. No. 15/221,106 dated Jul. 24, 2019. |
| Issue Notification for U.S. Appl. No. 15/238,427 dated Jul. 24, 2019. |
| Issue Notification for U.S. Appl. No. 15/260,103 dated Aug. 7, 2019. |
| Issue Notification for U.S. Appl. No. 15/611,587 dated Feb. 20, 2019. |
| Issue Notification for U.S. Appl. No. 15/612,325 dated Mar. 24, 2021. |
| Non-Final Office Action for U.S. Appl. No. 14/592,591 dated Mar. 20, 2020. |
| Non-Final Office Action for U.S. Appl. No. 14/722,613 dated Jun. 13, 2019. |
| Non-Final Office Action for U.S. Appl. No. 14/947,759 dated Mar. 17, 2016. |
| Non-Final Office Action for U.S. Appl. No. 14/952,591 dated Aug. 1, 2017. |
| Non-Final Office Action for U.S. Appl. No. 14/952,591 dated Mar. 20, 2020. |
| Non-Final Office Action for U.S. Appl. No. 14/952,591 dated Mar. 21, 2019. |
| Non-Final Office Action for U.S. Appl. No. 14/952,591 dated Sep. 28, 2018. |
| Non-Final Office Action for U.S. Appl. No. 15/171,968 dated May 11, 2020. |
| Non-Final Office Action for U.S. Appl. No. 15/171,968 dated Aug. 20, 2019. |
| Non-Final Office Action for U.S. Appl. No. 15/171,968 dated Jun. 12, 2018. |
| Non-Final Office Action for U.S. Appl. No. 15/221,106 dated Jun. 5, 2018. |
| Non-Final Office Action for U.S. Appl. No. 15/238,427 dated Aug. 8, 2018. |
| Non-Final Office Action for U.S. Appl. No. 15/260,103 dated Sep. 26, 2018. |
| Non-Final Office Action for U.S. Appl. No. 15/611,587 dated Dec. 29, 2017. |
| Non-Final Office Action for U.S. Appl. No. 15/611,587 dated Jul. 13, 2018. |
| Non-Final Office Action for U.S. Appl. No. 15/612,325 dated Mar. 19, 2020. |
| Non-Final Office Action for U.S. Appl. No. 16/899,956 dated Oct. 16, 2020. |
| Non-Final Office Action for U.S. Appl. No. 16/904,868 dated Nov. 25, 2020. |
| Non-Final Office Action for U.S. Appl. No. 16/905,400 dated Dec. 2, 2020. |
| Non-Final Office Action for U.S. Appl. No. 17/088,272 dated Jan. 25, 2021. |
| Non-Final Office Action for U.S. Appl. No. 29/624,661 dated Apr. 28, 2021. |
| Non-Final Office Action for U.S. Appl. No. 29/624,661 dated Jul. 18, 2019. |
| Non-Final Office Action for U.S. Appl. No. 29/694,002 dated Jun. 24, 2020. |
| Notice of Allowance for U.S. Appl. No. 14/952,591 dated Apr. 5, 2021. |
| Notice of Allowance for U.S. Appl. No. 15/171,968 dated Feb. 16, 2021. |
| Notice of Allowance for U.S. Appl. No. 15/171,968 dated Nov. 6, 2020. |
| Notice of Allowance for U.S. Appl. No. 15/221,106 dated May 1, 2019. |
| Notice of Allowance for U.S. Appl. No. 15/238,427 dated May 23, 2019. |
| Notice of Allowance for U.S. Appl. No. 15/260,103 dated Jun. 7, 2019. |
| Notice of Allowance for U.S. Appl. No. 15/611,587 dated Dec. 21, 2018. |
| Notice of Allowance for U.S. Appl. No. 15/612,325 dated Feb. 19, 2021. |
| Notice of Allowance for U.S. Appl. No. 15/612,325 dated Jan. 21, 2021. |
| Notice of Allowance for U.S. Appl. No. 29/624,661 dated Jul. 10, 2020. |
| Notice of Allowance for U.S. Appl. No. 29/624,661 dated May 14, 2020. |
| Notice of Allowance for U.S. Appl. No. 29/624,661 dated Sep. 29, 2020. |
| Notice of Allowance for U.S. Appl. No. 29/694,002 dated Jan. 29, 2021. |
| Notice of Allowance for U.S. Appl. No. 29/694,002 dated Oct. 16, 2020. |
| Notice to File Missing Parts for U.S. Appl. No. 17/179,116 dated Mar. 3, 2021. |
| U.S. Appl. No. 15/171,968, filed Jun. 2, 2016. |
| U.S. Appl. No. 15/221,106, filed Jul. 27, 2016. |
| U.S. Appl. No. 15/260,103, filed Sep. 8, 2016. |
| U.S. Appl. No. 16/369,676, filed Mar. 29, 2019. |
| U.S. Appl. No. 16/433,773, filed Jun. 6, 2019. |
| U.S. Appl. No. 16/449,039, filed Jun. 21, 2019. |
| U.S. Appl. No. 16/452,145, filed Jun. 25, 2019. |
| U.S. Appl. No. 16/452,258, filed Jun. 25, 2019. |
| U.S. Appl. No. 16/478,180, filed Jul. 16, 2019. |
| U.S. Appl. No. 16/904,868, filed Jun. 18, 2020. |
| U.S. Appl. No. 16/905,400, filed Jun. 18, 2020. |
| U.S. Appl. No. 17/051,550, filed Oct. 29, 2020. |
| U.S. Appl. No. 17/051,554, filed Oct. 29, 2020. |
| U.S. Appl. No. 17/051,585, filed Oct. 29, 2020. |
| U.S. Appl. No. 17/051,600, filed Oct. 29, 2020. |
| U.S. Appl. No. 17/088,272, filed Nov. 3, 2020. |
| U.S. Appl. No. 17/179,116, filed Feb. 18, 2021. |
| U.S. Appl. No. 29/741,751, filed Jul. 15, 2020. |
| U.S. Appl. No. 62/452,437, filed Jan. 31, 2017. |
| U.S. Appl. No. 62/665,297, filed May 1, 2018. |
| U.S. Appl. No. 62/665,302, filed May 1, 2018. |
| U.S. Appl. No. 62/665,317, filed May 1, 2018. |
| U.S. Appl. No. 62/665,321, filed May 1, 2018. |
| U.S. Appl. No. 62/665,331, filed May 1, 2018. |
| U.S. Appl. No. 62/665,335, filed May 1, 2018. |
| U.S. Appl. No. 62/853,279, filed May 28, 2019. |
| U.S. Appl. No. 62/853,889, filed May 29, 2019. |
| U.S. Appl. No. 62/864,656, filed Jun. 21, 2019. |
| U.S. Appl. No. 62/873,045, filed Jul. 11, 2019. |
| U.S. Appl. No. 62/873,048, filed Jul. 11, 2019. |
| U.S. Appl. No. 62/876,500, filed Jul. 19, 2019. |
| U.S. Appl. No. 62/877,558, filed Jul. 23, 2019. |
| U.S. Appl. No. 62/883,172, filed Aug. 6, 2019. |
| U.S. Appl. No. 62/889,149, filed Aug. 20, 2019. |
| U.S. Appl. No. 62/994,912, filed Mar. 26, 2020. |
| U.S. Appl. No. 63/011,445, filed Apr. 17, 2020. |
| U.S. Appl. No. 63/011,487, filed Apr. 17, 2020. |
| U.S. Appl. No. 63/011,571, filed Apr. 17, 2020. |
| U.S. Appl. No. 63/011,657, filed Apr. 17, 2020. |
| U.S. Appl. No. 63/011,760, filed Apr. 17, 2020. |
| U.S. Appl. No. 63/012,347, filed Apr. 20, 2020. |
| U.S. Appl. No. 63/012,384, filed Apr. 20, 2020. |
| U.S. Appl. No. 63/030,685, filed May 27, 2020. |
| U.S. Appl. No. 63/061,241, filed Aug. 5, 2020. |
| U.S. Appl. No. 63/061,244, filed Aug. 5, 2020. |
| U.S. Appl. No. 63/061,834, filed Aug. 6, 2020. |
| U.S. Appl. No. 63/064,017, filed Aug. 11, 2020. |
| U.S. Appl. No. 63/064,126, filed Aug. 11, 2020. |
| U.S. Appl. No. 63/071,438, filed Aug. 28, 2020. |
| U.S. Appl. No. 63/074,051, filed Sep. 3, 2020. |
| U.S. Appl. No. 63/074,066, filed Sep. 3, 2020. |
| U.S. Appl. No. 63/076,032, filed Sep. 9, 2020. |
| U.S. Appl. No. 63/076,474, filed Sep. 10, 2020. |
| U.S. Appl. No. 63/076,477, filed Sep. 10, 2020. |
| U.S. Appl. No. 63/082,261, filed Sep. 23, 2020. |
| U.S. Appl. No. 63/088,506, filed Oct. 7, 2020. |
| U.S. Appl. No. 63/088,511, filed Oct. 7, 2020. |
| U.S. Appl. No. 63/094,464, filed Oct. 21, 2020. |
| U.S. Appl. No. 63/094,498, filed Oct. 21, 2020. |
| U.S. Appl. No. 63/094,594, filed Oct. 21, 2020. |
| U.S. Appl. No. 63/094,608, filed Oct. 21, 2020. |
| U.S. Appl. No. 63/094,626, filed Oct. 21, 2020. |
| U.S. Appl. No. 63/109,066, filed Nov. 3, 2020. |
| U.S. Appl. No. 63/112,417, filed Nov. 11, 2020. |
| U.S. Appl. No. 63/119,161, filed Nov. 30, 2020. |
| U.S. Appl. No. 63/146,946, filed Feb. 8, 2021. |
| U.S. Appl. No. 63/147,299, filed Feb. 9, 2021. |
| U.S. Appl. No. 63/165,273, filed Mar. 24, 2021. |
| U.S. Appl. No. 63/165,384, filed Mar. 24, 2021. |
| U.S. Appl. No. 63/171,165, filed Apr. 6, 2021. |
| U.S. Appl. No. 63/172,975, filed Apr. 9, 2021. |
| U.S. Appl. No. 63/181,695, filed Apr. 29, 2021. |
| Defendant and Counterclaim Plaintiff Sage Products, LLC's Answer, Defenses, and Counterclaims to Plaintiff's Amended Complaint, Nov. 1, 2019. |
| Memorandum Order, Feb. 2021, 14 pgs. |
| Sage's Initial Invalidity Contentions Regarding U.S. Pat. Nos. 8,287,508; 10,226,375; and 10,390,989, May 29, 2020, 193 pages. |
| Sage's Supplemental and Initial Invalidity Contentions Regarding U.S. Pat. No.'s 8,287,508; 10,226,375; 10,390,989 and Initial Invalidity Contentions Regarding U.S. Pat. No. 10,376,407, Aug. 21, 2020, 277 pages. |
| Sage's Second Supplemental Invalidity Contentions Regarding U.S. Pat. Nos. 8,287,508, 10,226,375, 10,390,989, and 10,376,407, 292 pages. |
| Boehringer CareDry System—Second Generation for Non-Invasive Urinary Management for Females, Mar. 2021, 3 pgs. |
| Excerpts from the 508 (U.S. Pat. No. 8,278,508) Patent's Prosecution History, 2020, 99 pages. |
| Plaintiff's Opening Claim Construction Brief, Case No. 19-1508-MN, Oct. 16, 2020, 26 pages. |
| Plaintiff's Identification of Claim Terms and Proposed Constructions, Case No. 19-1508-MN, 3 pages. |
| PureWick's Response to Interrogatory No. 9 in PureWick, LLC v. Sage Products, LLC, Case No. 19-1508-MN, Mar. 23, 2020, 6 pages. |
| Sage's Preliminary Identification of Claim Elements and Proposed Constructions for U.S. Pat. Nos. 8,287,508, 10,226,376, 10,390,989 and 10,376,407, Case No. 19-1508-MN, 7 pages. |
| Decision Granting Institution of Inter Partes Review for U.S. Pat. No. 8,287,508, Case No. 2020-01426, Feb. 17, 2021, 39 pages. |
| Corrected Certificate of Service, Case No. IPR2020-01426, U.S. Pat. No. 8,287,508, 2020, 2 pages. |
| Declaration of Diane K. Newman Curriculum Vitae, Petition for Interparties Review, 2020, pp. 1-199. |
| “3 Devices Take Top Honors in Dare-to-Dream Medtech Design Contest”, R+D Digest, Nov. 2013, 1 page. |
| “Advanced Mission Extender Device (AMDX) Products”, Omni Medical Systems, Inc., 15 pages. |
| “AMXD Control Starter Kit Brochure”, https://www.omnimedicalsys.com/index.php?page=products, Omni Medical, 8 pages. |
| “AMXDmax In-Flight Bladder Relief”, Omni Medical; Omni Medical Systems, Inc., 2015. |
| “AMXDX—Advanced Mission Extender Device Brochure”, Omni Medical, Omni Brochure—http://www.omnimedicalsys.com/uploads/AMXDFixedWing.pdf, 2 pages. |
| “External Urine Management for Female Anatomy”, https://www.stryker.com/us/en/sage/products/sage-primafit.html, Jul. 2020, 4 pages. |
| “High Absorbancy Cellulose Acetate Electrospun Nanofibers for Feminine Hygiene Application”, https://www.sciencedirect.com/science/article/abs/pii/S2352940716300701?via%3Dihub, Jul. 2016, 3 pages. |
| “How Period Panties Work”, www.shethinx.com/pages/thinx-itworks, 2020, 10 pages. |
| “Hydrogel properties of electrospun polyvinylpyrrolidone and polyvinylpyrrolidone/poly(acrylic acid) blend nanofibers”, https://pubs.rsc.org/en/content/articlelanding/2015/ra/c5ra07514a#!divAbstract, 2015, 5 pages. |
| “In Flight Bladder Relief”, Omni Medical, Omni Presentation https://www.omnimedicalsys.com/uploads/AMXDmax_HSD.pdf, 14 pages. |
| “Making Women's Sanitary Products Safer and Cheaper”, https://www.elsevier.com/connect/making-womens-sanitary-products-safer-and-cheaper, Sep. 2016, 10 pages. |
| “Novel Nanofibers Make Safe and Effective Absorbent for Sanitary Products”, https://www.materialstoday.com/nanomaterials/news/nanofibers-make-safe-and-effective-absorbent/, Oct. 2016, 3 pages. |
| “Research and Development Work Relating to Assistive Technology 2005-06”, British Department of Health, Nov. 2006, 40 pages. |
| “Step by Step How Ur24 WorksHome”, http://medicalpatentur24.com, last accessed Dec. 6, 2017, Aug. 30, 2017, 4 pages. |
| “Underwear that absorbs your period”, Thinx!, https://www.shethinx.com/pages/thinx-it-works last accessed Jun. 24, 2020, 7 pages. |
| “User & Maintenance Guide”, Omni Medical, 2007, 16 pages. |
| “Winners Announced for Dare-to-Dream Medtech Design Challenge”, https://www.mddionline.com/design-engineering/winners-announced-dare-dream-medtech-design-challenge, MD&DI, 2014, 4 pages. |
| Hollister, Female Urinary and Pouch and Male Urinary Pouch Brochure, 2011, 1 page. |
| Hollister, “Male Urinary Pouch External Collection Device”, http://www.hollister.com/en/products/Continence-Care-Products/Urine-Collectors/Urine-Collection-Accessories/Male-Urinary-Pouch-External-Collection-Device, last accessed Feb. 8, 2018. |
| Hollister, “Retracted Penis Pouch by Hollister”, Vitality Medical.com, https://www.vitalitymedical.com/hollister-retracted-penis-pouch.html last accessed Jun. 24, 2020, 6 pages. |
| Macaulay, et al., “A Noninvasive Continence Management System: Development and Evaluation of a Novel Toileting Device for Women”, The Wound, Ostomy and Continence Nurses Society, vol. 34 No. 6, 2007, pp. 641-648. |
| Newman, et al., “The Urinary Incontinence Sourcebook”, Petition for Interparties Review, 1997, 23 pages. |
| Newton, et al., “Measuring Safety, Effectiveness and Ease of Use of PureWick in the Management of Urinary Incontinence in Bedbound Women: Case Studies”, Jan. 8, 2016, 11 pages. |
| Parmar, “10 Finalists Chosen for Dare-to-Dream Medtech Design Challenge (PureWick)”, Design Services, Nov. 10, 2014, 3 pages. |
| Purewick, “Incontinence Relief for Women”, Presentation, Sep. 23, 2015, 7 pages. |
| Pytlik, “Super Absorbent Polymers”, University of Buffalo, http://www.courses.sens.buffalo.edu/ce435/Diapers/Diapers.html, accessed on Feb. 17, 2017. |
| Sachtman, “New Relief for Pilots? It Depends”, Wired, https://www.wired.com/2008/05/pilot-relief/, 2008, 2 pages. |
| Advisory Action for U.S. Appl. No. 16/245,726 dated Apr. 19, 2023. |
| Advisory Action for U.S. Appl. No. 16/369,676 dated Mar. 24, 2023. |
| Advisory Action for U.S. Appl. No. 16/433,773 dated Feb. 15, 2023. |
| Advisory Action for U.S. Appl. No. 16/452,258 dated Oct. 26, 2022. |
| Advisory Action for U.S. Appl. No. 16/478,180 dated Sep. 21, 2022. |
| Advisory Action for U.S. Appl. No. 16/899,956 dated Jul. 9, 2021. |
| Advisory Action for U.S. Appl. No. 16/904,868 dated Jul. 2, 2021. |
| Advisory Action for U.S. Appl. No. 16/904,868 dated Jun. 15, 2022. |
| Advisory Action for U.S. Appl. No. 16/905,400 dated Feb. 16, 2022. |
| Advisory Action for U.S. Appl. No. 16/905,400 dated Jun. 9, 2021. |
| Advisory Action for U.S. Appl. No. 17/662,700 dated Jan. 30, 2023. |
| Corrected Notice of Allowability for U.S. Appl. No. 17/330,657 dated Dec. 9, 2021. |
| Final Office Action for U.S. Appl. No. 16/245,726 dated Nov. 25, 2022. |
| Final Office Action for U.S. Appl. No. 16/369,676 dated Dec. 5, 2022. |
| Final Office Action for U.S. Appl. No. 16/433,773 dated Oct. 25, 2022. |
| Final Office Action for U.S. Appl. No. 16/449,039 dated Aug. 1, 2022. |
| Final Office Action for U.S. Appl. No. 16/452,145 dated Mar. 25, 2022. |
| Final Office Action for U.S. Appl. No. 16/452,258 dated Jun. 14, 2022. |
| Final Office Action for U.S. Appl. No. 16/478,180 dated Jun. 22, 2022. |
| Final Office Action for U.S. Appl. No. 16/478,180 dated May 31, 2023. |
| Final Office Action for U.S. Appl. No. 16/904,868 dated Mar. 10, 2022. |
| Final Office Action for U.S. Appl. No. 16/905,400 dated Dec. 9, 2021. |
| Final Office Action for U.S. Appl. No. 17/051,399 dated Mar. 9, 2023. |
| Final Office Action for U.S. Appl. No. 17/051,550 dated May 23, 2023. |
| Final Office Action for U.S. Appl. No. 17/088,272 dated May 25, 2021. |
| Final Office Action for U.S. Appl. No. 17/444,792 dated Jun. 15, 2023. |
| Final Office Action for U.S. Appl. No. 17/451,345 dated May 3, 2023. |
| Final Office Action for U.S. Appl. No. 17/662,700 dated Sep. 30, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/IB2021/057173 dated Nov. 5, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/057562 dated Jan. 27, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/061563 dated Feb. 19, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/065234 dated Apr. 12, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/067451 dated Mar. 25, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/067454 dated Mar. 29, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/067455 dated Mar. 26, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/015024 dated May 18, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/015787 dated May 27, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/023001 dated Jun. 21, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/024162 dated Jul. 8, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/026607 dated Jul. 29, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/027061 dated Jul. 19, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/027104 dated Jul. 6, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/027314 dated Jul. 6, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/027422 dated Aug. 12, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/027425 dated Aug. 11, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/027913 dated Jul. 12, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/027917 dated Aug. 19, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/039866 dated Oct. 7, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/043893 dated Nov. 22, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/044699 dated Nov. 22, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/045188 dated Jan. 26, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/047536 dated Dec. 23, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/048211 dated Dec. 22, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/048661 dated Feb. 14, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/049404 dated Jan. 18, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/051456 dated Jan. 19, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/053593 dated Apr. 11, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/055515 dated Jan. 28, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/056566 dated Feb. 11, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/060993 dated Mar. 18, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/062440 dated Mar. 28, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/011108 dated Apr. 22, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/011281 dated Apr. 25, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/011419 dated Jun. 7, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/011421 dated Jun. 13, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/012794 dated May 3, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/014285 dated Sep. 28, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/014749 dated Sep. 28, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015026 dated Oct. 31, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015045 dated Sep. 9, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015073 dated Sep. 8, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015418 dated Nov. 11, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015420 dated Nov. 18, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015471 dated May 16, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015492 dated Apr. 26, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015781 dated May 6, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/016942 dated Jun. 8, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/018159 dated Dec. 12, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/018170 dated May 31, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/019254 dated Jun. 7, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/019480 dated Jun. 13, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/021103 dated Jun. 23, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/022111 dated Oct. 26, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/023594 dated Jul. 12, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/026667 dated Aug. 22, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/030685 dated Oct. 31, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/031032 dated Sep. 9, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/032424 dated Oct. 11, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/034457 dated Oct. 12, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/034744 dated Dec. 9, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/039018 dated Jan. 10, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/039022 dated Jan. 10, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/039711 dated Jan. 12, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/039714 dated Nov. 22, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/041085 dated Mar. 16, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/041688 dated Nov. 21, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/042719 dated Dec. 5, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/042725 dated Dec. 19, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/044107 dated Dec. 23, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/044212 dated Jan. 20, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/044243 dated Feb. 24, 2023. |
| Issue Notification for U.S. Appl. No. 14/952,591 dated Jul. 28, 2021. |
| Issue Notification for U.S. Appl. No. 16/899,956 dated Mar. 29, 2023. |
| Issue Notification for U.S. Appl. No. 16/905,400 dated Nov. 30, 2022. |
| Issue Notification for U.S. Appl. No. 17/088,272 dated Jun. 15, 2022. |
| Issue Notification for U.S. Appl. No. 17/330,657 dated Jun. 22, 2022. |
| Issue Notification for U.S. Appl. No. 29/624,661 dated Aug. 4, 2021. |
| Non-Final Office Action for U.S. Appl. No. 16/245,726 dated Jan. 21, 2022. |
| Non-Final Office Action for U.S. Appl. No. 16/369,676 dated Mar. 31, 2022. |
| Non-Final Office Action for U.S. Appl. No. 16/433,773 dated Apr. 11, 2023. |
| Non-Final Office Action for U.S. Appl. No. 16/433,773 dated Apr. 21, 2022. |
| Non-Final Office Action for U.S. Appl. No. 16/449,039 dated Apr. 27, 2023. |
| Non-Final Office Action for U.S. Appl. No. 16/449,039 dated Dec. 8, 2021. |
| Non-Final Office Action for U.S. Appl. No. 16/452,145 dated Mar. 28, 2023. |
| Non-Final Office Action for U.S. Appl. No. 16/452,145 dated Sep. 28, 2021. |
| Non-Final Office Action for U.S. Appl. No. 16/452,258 dated Apr. 26, 2023. |
| Non-Final Office Action for U.S. Appl. No. 16/452,258 dated Sep. 28, 2021. |
| Non-Final Office Action for U.S. Appl. No. 16/478,180 dated Dec. 20, 2022. |
| Non-Final Office Action for U.S. Appl. No. 16/478,180 dated Oct. 22, 2021. |
| Non-Final Office Action for U.S. Appl. No. 16/899,956 dated Sep. 2, 2021. |
| Non-Final Office Action for U.S. Appl. No. 16/904,868 dated Mar. 15, 2023. |
| Non-Final Office Action for U.S. Appl. No. 16/904,868 dated Oct. 5, 2021. |
| Non-Final Office Action for U.S. Appl. No. 16/905,400 dated Apr. 27, 2022. |
| Non-Final Office Action for U.S. Appl. No. 16/905,400 dated Jul. 22, 2021. |
| Non-Final Office Action for U.S. Appl. No. 17/051,550 dated Dec. 15, 2022. |
| Non-Final Office Action for U.S. Appl. No. 17/051,585 dated Mar. 29, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/179,116 dated Mar. 24, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/330,657 dated Aug. 11, 2021. |
| Non-Final Office Action for U.S. Appl. No. 17/444,792 dated Feb. 10, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/446,256 dated Apr. 13, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/448,811 dated Mar. 1, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/450,864 dated May 10, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/451,345 dated Dec. 7, 2022. |
| Non-Final Office Action for U.S. Appl. No. 17/451,354 dated May 3, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/453,260 dated Mar. 14, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/501,591 dated Apr. 25, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/653,137 dated Apr. 7, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/655,464 dated Mar. 14, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/662,700 dated Jul. 22, 2022. |
| Non-Final Office Action for U.S. Appl. No. 17/664,487 dated Jun. 8, 2023. |
| Non-Final Office Action for U.S. Appl. No. 29/741,751 dated Jan. 18, 2022. |
| Notice of Allowance for U.S. Appl. No. 14/952,591 dated Jul. 8, 2021. |
| Notice of Allowance for U.S. Appl. No. 16/449,039 dated Dec. 15, 2022. |
| Notice of Allowance for U.S. Appl. No. 16/899,956 dated Apr. 19, 2022. |
| Notice of Allowance for U.S. Appl. No. 16/899,956 dated Aug. 10, 2022. |
| Notice of Allowance for U.S. Appl. No. 16/899,956 dated Dec. 1, 2022. |
| Notice of Allowance for U.S. Appl. No. 16/899,956 dated Dec. 29, 2021. |
| Notice of Allowance for U.S. Appl. No. 16/905,400 dated Aug. 17, 2022. |
| Notice of Allowance for U.S. Appl. No. 17/088,272 dated Aug. 5, 2021. |
| Notice of Allowance for U.S. Appl. No. 17/088,272 dated Mar. 4, 2022. |
| Notice of Allowance for U.S. Appl. No. 17/088,272 dated Nov. 24, 2021. |
| Notice of Allowance for U.S. Appl. No. 17/330,657 dated Mar. 16, 2022. |
| Notice of Allowance for U.S. Appl. No. 17/330,657 dated Nov. 26, 2021. |
| Notice of Allowance for U.S. Appl. No. 17/461,036 dated Feb. 22, 2023. |
| Notice of Allowance for U.S. Appl. No. 17/461,036 dated Oct. 6, 2022. |
| Notice of Allowance for U.S. Appl. No. 17/662,700 dated Mar. 28, 2023. |
| Notice of Allowance for U.S. Appl. No. 17/663,046 dated Jan. 30, 2023. |
| Notice of Allowance for U.S. Appl. No. 29/624,661 dated Apr. 28, 2021. |
| Notice of Allowance for U.S. Appl. No. 29/694,002 dated Apr. 29, 2021. |
| Notice of Allowance for U.S. Appl. No. 29/741,751 dated Jun. 9, 2022. |
| Restriction Requirement for U.S. Appl. No. 16/433,773 dated Dec. 7, 2021. |
| Restriction Requirement for U.S. Appl. No. 16/478,180 dated May 25, 2021. |
| Restriction Requirement for U.S. Appl. No. 17/446,256 dated Jan. 23, 2023. |
| Restriction Requirement for U.S. Appl. No. 17/646,771 dated Apr. 6, 2023. |
| Text Messages to Lorena Eckert Re Prototype PureWick Holder dated Apr. 16, 2022. |
| U.S. Appl. No. 14/625,469, filed Feb. 28, 2015. |
| U.S. Appl. No. 14/947,759, filed Nov. 20, 2015. |
| U.S. Appl. No. 14/952,591, filed Nov. 25, 2015. |
| U.S. Appl. No. 15/384,196, filed Dec. 19, 2016. |
| U.S. Appl. No. 16/245,726, filed Jan. 11, 2019. |
| U.S. Appl. No. 17/330,657, filed May 26, 2021. |
| U.S. Appl. No. 17/378,015, filed Jul. 16, 2021. |
| U.S. Appl. No. 17/394,055, filed Aug. 4, 2021. |
| U.S. Appl. No. 17/444,825, filed Aug. 10, 2021. |
| U.S. Appl. No. 17/446,256, filed Aug. 27, 2021. |
| U.S. Appl. No. 17/446,654, filed Sep. 1, 2021. |
| U.S. Appl. No. 17/447,123, filed Sep. 8, 2021. |
| U.S. Appl. No. 17/450,864, filed Oct. 14, 2021. |
| U.S. Appl. No. 17/451,345, filed Oct. 19, 2021. |
| U.S. Appl. No. 17/451,354, filed Oct. 19, 2021. |
| U.S. Appl. No. 17/453,260, filed Nov. 2, 2021. |
| U.S. Appl. No. 17/453,560, filed Nov. 4, 2021. |
| U.S. Appl. No. 17/461,036, filed Aug. 30, 2021. |
| U.S. Appl. No. 17/501,591, filed Oct. 14, 2021. |
| U.S. Appl. No. 17/595,747, filed Nov. 23, 2021. |
| U.S. Appl. No. 17/597,408, filed Jan. 5, 2022. |
| U.S. Appl. No. 17/597,673, filed Jan. 18, 2022. |
| U.S. Appl. No. 17/614,173, filed Nov. 24, 2021. |
| U.S. Appl. No. 17/631,619, filed Jan. 31, 2022. |
| U.S. Appl. No. 17/645,821, filed Dec. 23, 2021. |
| U.S. Appl. No. 17/646,771, filed Jan. 3, 2022. |
| U.S. Appl. No. 17/653,314, filed Mar. 3, 2022. |
| U.S. Appl. No. 17/653,920, filed Mar. 8, 2022. |
| U.S. Appl. No. 17/655,464, filed Mar. 18, 2022. |
| U.S. Appl. No. 17/657,474, filed Mar. 31, 2022. |
| U.S. Appl. No. 17/661,090, filed Apr. 28, 2022. |
| U.S. Appl. No. 17/662,700, filed May 10, 2022. |
| U.S. Appl. No. 17/663,046, filed May 12, 2022. |
| U.S. Appl. No. 17/664,487, filed May 23, 2022. |
| U.S. Appl. No. 17/664,914, filed May 25, 2022. |
| U.S. Appl. No. 17/749,340, filed May 20, 2022. |
| U.S. Appl. No. 17/754,736, filed Apr. 11, 2022. |
| U.S. Appl. No. 17/756,201, filed May 19, 2022. |
| U.S. Appl. No. 17/758,152, filed Jun. 29, 2022. |
| U.S. Appl. No. 17/758,316, filed Jul. 1, 2022. |
| U.S. Appl. No. 17/759,697, filed Jul. 28, 2022. |
| U.S. Appl. No. 17/878,268, filed Aug. 1, 2022. |
| U.S. Appl. No. 17/907,125, filed Sep. 23, 2022. |
| U.S. Appl. No. 17/912,147, filed Sep. 16, 2022. |
| U.S. Appl. No. 17/929,887, filed Sep. 6, 2022. |
| U.S. Appl. No. 17/930,238, filed Sep. 7, 2022. |
| U.S. Appl. No. 17/933,590, filed Sep. 20, 2022. |
| U.S. Appl. No. 17/996,064, filed Oct. 12, 2022. |
| U.S. Appl. No. 17/996,155, filed Oct. 13, 2022. |
| U.S. Appl. No. 17/996,253, filed Oct. 14, 2022. |
| U.S. Appl. No. 17/996,468, filed Oct. 18, 2022. |
| U.S. Appl. No. 17/996,556, filed Oct. 19, 2022. |
| U.S. Appl. No. 18/003,029, filed Dec. 22, 2022. |
| U.S. Appl. No. 18/006,807, filed Jan. 25, 2023. |
| U.S. Appl. No. 18/007,105, filed Jan. 27, 2023. |
| U.S. Appl. No. 18/041,109, filed Feb. 9, 2023. |
| U.S. Appl. No. 18/042,842, filed Feb. 24, 2023. |
| U.S. Appl. No. 18/043,618, filed Mar. 1, 2023. |
| U.S. Appl. No. 18/115,444, filed Feb. 28, 2023. |
| U.S. Appl. No. 18/134,857, filed Apr. 14, 2023. |
| U.S. Appl. No. 18/140,163, filed Apr. 27, 2023. |
| U.S. Appl. No. 18/140,751, filed Apr. 28, 2023. |
| U.S. Appl. No. 18/164,800, filed Feb. 6, 2023. |
| U.S. Appl. No. 18/198,464, filed May 17, 2023. |
| U.S. Appl. No. 18/246,121, filed Mar. 21, 2023. |
| U.S. Appl. No. 18/247,986, filed Apr. 5, 2023. |
| U.S. Appl. No. 18/265,736, filed Jun. 7, 2023. |
| U.S. Appl. No. 18/299,788, filed Apr. 13, 2023. |
| U.S. Appl. No. 18/335,579, filed Jun. 15, 2023. |
| U.S. Appl. No. 61/955,537, filed Mar. 19, 2014. |
| U.S. Appl. No. 62/082,279, filed Nov. 20, 2014. |
| U.S. Appl. No. 62/084,078, filed Nov. 25, 2014. |
| U.S. Appl. No. 62/414,963, filed Oct. 31, 2016. |
| U.S. Appl. No. 62/485,578, filed Apr. 14, 2017. |
| U.S. Appl. No. 62/923,279, filed Oct. 18, 2019. |
| U.S. Appl. No. 62/926,767, filed Oct. 28, 2019. |
| U.S. Appl. No. 62/935,337, filed Nov. 14, 2019. |
| U.S. Appl. No. 62/938,447, filed Nov. 21, 2019. |
| U.S. Appl. No. 62/949,187, filed Dec. 17, 2019. |
| U.S. Appl. No. 62/956,756, filed Jan. 3, 2020. |
| U.S. Appl. No. 62/956,767, filed Jan. 3, 2020. |
| U.S. Appl. No. 62/956,770, filed Jan. 3, 2020. |
| U.S. Appl. No. 62/967,158, filed Jan. 26, 2020. |
| U.S. Appl. No. 62/967,977, filed Jan. 30, 2020. |
| U.S. Appl. No. 62/991,754, filed Mar. 19, 2020. |
| U.S. Appl. No. 63/008,112, filed Apr. 10, 2020. |
| U.S. Appl. No. 63/047,374, filed Jul. 2, 2020. |
| U.S. Appl. No. 63/067,542, filed Aug. 19, 2020. |
| U.S. Appl. No. 63/073,545, filed Sep. 2, 2020. |
| U.S. Appl. No. 63/073,553, filed Sep. 2, 2020. |
| U.S. Appl. No. 63/094,646, filed Oct. 21, 2020. |
| U.S. Appl. No. 63/109,084, filed Nov. 3, 2020. |
| U.S. Appl. No. 63/124,271, filed Dec. 11, 2020. |
| U.S. Appl. No. 63/133,892, filed Jan. 5, 2021. |
| U.S. Appl. No. 63/134,287, filed Jan. 6, 2021. |
| U.S. Appl. No. 63/134,450, filed Jan. 6, 2021. |
| U.S. Appl. No. 63/134,631, filed Jan. 7, 2021. |
| U.S. Appl. No. 63/134,632, filed Jan. 7, 2021. |
| U.S. Appl. No. 63/134,754, filed Jan. 7, 2021. |
| U.S. Appl. No. 63/138,878, filed Jan. 19, 2021. |
| U.S. Appl. No. 63/147,013, filed Feb. 8, 2021. |
| U.S. Appl. No. 63/148,723, filed Feb. 12, 2021. |
| U.S. Appl. No. 63/154,248, filed Feb. 26, 2021. |
| U.S. Appl. No. 63/155,395, filed Mar. 2, 2021. |
| U.S. Appl. No. 63/157,007, filed Mar. 5, 2021. |
| U.S. Appl. No. 63/157,014, filed Mar. 5, 2021. |
| U.S. Appl. No. 63/159,142, filed Mar. 10, 2021. |
| U.S. Appl. No. 63/159,186, filed Mar. 10, 2021. |
| U.S. Appl. No. 63/159,210, filed Mar. 10, 2021. |
| U.S. Appl. No. 63/191,558, filed May 21, 2021. |
| U.S. Appl. No. 63/192,274, filed May 24, 2021. |
| U.S. Appl. No. 63/192,289, filed May 24, 2021. |
| U.S. Appl. No. 63/193,235, filed May 26, 2021. |
| U.S. Appl. No. 63/193,406, filed May 26, 2021. |
| U.S. Appl. No. 63/193,891, filed May 27, 2021. |
| U.S. Appl. No. 63/208,262, filed Jun. 8, 2021. |
| U.S. Appl. No. 63/214,551, filed Jun. 24, 2021. |
| U.S. Appl. No. 63/214,570, filed Jun. 24, 2021. |
| U.S. Appl. No. 63/215,017, filed Jun. 25, 2021. |
| U.S. Appl. No. 63/228,244, filed Aug. 2, 2021. |
| U.S. Appl. No. 63/228,252, filed Aug. 2, 2021. |
| U.S. Appl. No. 63/228,258, filed Aug. 2, 2021. |
| U.S. Appl. No. 63/230,894, filed Aug. 9, 2021. |
| U.S. Appl. No. 63/230,897, filed Aug. 9, 2021. |
| U.S. Appl. No. 63/238,457, filed Aug. 30, 2021. |
| U.S. Appl. No. 63/238,477, filed Aug. 30, 2021. |
| U.S. Appl. No. 63/241,328, filed Sep. 7, 2021. |
| U.S. Appl. No. 63/241,562, filed Sep. 8, 2021. |
| U.S. Appl. No. 63/241,564, filed Sep. 8, 2021. |
| U.S. Appl. No. 63/241,575, filed Sep. 8, 2021. |
| U.S. Appl. No. 63/246,972, filed Sep. 22, 2021. |
| U.S. Appl. No. 63/247,375, filed Sep. 23, 2021. |
| U.S. Appl. No. 63/247,478, filed Sep. 23, 2021. |
| U.S. Appl. No. 63/247,491, filed Sep. 23, 2021. |
| U.S. Appl. No. 63/299,208, filed Jan. 13, 2022. |
| U.S. Application No. 63/308, 190 filed Feb. 9, 2022. |
| PureWick Corporation v. Sage Products, LLC Transcripts vol. 5, Apr. 1, 2022, 72 pages. |
| PureWick Corporation v. Sage Products, LLC Transcripts vol. 1, Mar. 28, 2022, 99 pages. |
| PureWick Corporation v. Sage Products, LLC Transcripts vol. 2, Mar. 29, 2022, 106 pages. |
| PureWick Corporation v. Sage Products, LLC Transcripts vol. 3, Mar. 30, 2022, 115 pages. |
| PureWick Corporation v. Sage Products, LLC Transcripts vol. 4, Mar. 31, 2022, 117 pages. |
| “AMXD Control Starter Kit”, Omni Medical Systems, Inc., 1 page. |
| “AMXDmax Advanced Mission Extender Device User & Maintenance Guide”, Omni Medical, Jan. 11, 2010, 10 pages. |
| “AMXDmax Development History 2002-2014”, Omni Medical Systems, Inc., 2 pages. |
| “Combat Force Multiplier in Flight Bladder Relief Cockpit Essential Equipment Brochure”, Omni Medical, 20 pages. |
| “GSA Price List”, Omni Medical, Apr. 2011, 2 pages. |
| “How is Polypropylene Fiber Made”, https:www.yarnsandfibers.com/textile-resources/synthetic-fibers/polypropylene-fiber/polypropylene-fiber-production-raw-materials/how-is-polypropylene-fiber-made/ last accessed 2020, Oct. 7, 2020, 3 pages. |
| “Letter to Mark Harvie of Omni Measurement Systems”, Department of Veterans Affairs, Nov. 1, 2007, 11 pages. |
| “Revised AMXDmax Advanced Mission Extender Device User & Maintenance Guide”, Omni Medical Systems, Oct. 8, 2019, 52 pages. |
| “Rising Warrior Insulated Gallon Jug Cover”, https://www.amazon.com/Rising-Warrior-Insulated-Sleeve, 2021, 2 pages. |
| “Urine Bag Cover—Catheter Bag Cover 2000 ml Volume—Medline Style—Multiple Sclerosis—Spine Injury—Suprapublic Catheter—Bladder Incontinence”, https://www.etsy.com/listing/1142934658/urine-bag-cover-caatheter-bag-cover-2000, 2022, 1 page. |
| “Vinyl Dust Cover, Janome #741811000, Janome, Sewing Parts Online”, https://www.sewingpartsonline.com/vinyl-dust-cover-janome-74181000, 2020, 2 pages. |
| Ali , “Sustainability Assessment: Seventh Generation Diapers versus gDiapers”, The University of Vermont, Dec. 6, 2011, pp. 1-31. |
| Autumn , et al., “Frictional adhesion: a new angle on gecko attachment”, The Journal of Experimental Biology, 2006, pp. 3569-3579. |
| Cañas , et al., “Effect of nano- and micro-roughness on adhesion of bioinspired micropatterned surfaces”, Acta Biomaterialia 8, 2012, pp. 282-288. |
| Chaudhary , et al., “Bioinspired dry adhesive: Poly(dimethylsiloxane) grafted with poly(2-ethylhexyl acrylate) brushes”, European Polymer Journal, 2015, pp. 432-440. |
| Dai , et al., “Non-sticky and Non-slippery Biomimetic Patterned Surfaces”, Journal of Bionic Engineering, Mar. 2020, pp. 326-334. |
| Espinoza-Ramirez , “Nanobiodiversity and Biomimetic Adhesives Development: From Nature to Production and Application”, Journal of Biomaterials and Nanobiotechnology, pp. 78-101, 2019. |
| Hwang , et al., “Multifunctional Smart Skin Adhesive Patches for Advanced Health Care”, Adv. Healthcare Mater, 2018, pp. 1-20. |
| Jagota , et al., “Adhesion, friction, and compliance of bio-mimetic and bio-inspired structured interfaces”, Materials Science and Engineering, 2011, pp. 253-292. |
| Jeong , et al., “A nontransferring dry adhesive with hierarchical polymer nanohairs”, PNAS, Apr. 7, 2009, pp. 5639-5644. |
| Jeong , et al., “Nanohairs and nanotubes: Efficient structural elements for gecko-inspired artificial dry adhesives”, Science Direct, 2009, pp. 335-346. |
| Karp , et al., “Dry solution to a sticky problem”, Nature., 2011, pp. 42-43. |
| Lee, et al., “Continuous Fabrication of Wide-Tip Microstructures for Bio-Inspired Dry Adhesives via Tip Inking Process”, Journal of Chemistry, Jan. 2, 2019, pp. 1-5. |
| Parness , et al., “A microfabricated wedge-shaped adhesive array displaying gecko-like dynamic adhesion, directionality”, J.R. Soc. Interface, 2009, pp. 1223-1232. |
| Pieper , et al., “An external urine-collection device for women: A clinical trial”, Journal of ER Nursing, vol. 20, No. 2, Mar./Apr. 1993, pp. 51-55. |
| Tsipenyuk , et al., “Use of biomimetic hexagonal surface texture in friction against lubricated skin”, Journal of The Royal Society—Interface, 2014, pp. 1-6. |
| Vinas , “A Solution for an Awkward—But Serious—Subject”, http://www.aero-news.net/index.cfm?do=main.textpost&id=69ae2bb1-838b-4098-a7b5-7flbb2505688 last accessed Feb. 8, 2021, 3 pages. |
| Advisory Action for U.S. Appl. No. 16/478,180 dated Sep. 7, 2023. |
| Advisory Action for U.S. Appl. No. 17/051,550 dated Sep. 8, 2023. |
| Advisory Action for U.S. Appl. No. 17/444,792 dated Aug. 25, 2023. |
| Final Office Action for U.S. Appl. No. 16/369,676 dated Aug. 31, 2023. |
| Final Office Action for U.S. Appl. No. 17/051,585 dated Jul. 27, 2023. |
| Final Office Action for U.S. Appl. No. 17/446,256 dated Sep. 19, 2023. |
| Final Office Action for U.S. Appl. No. 17/448,811 dated Aug. 3, 2023. |
| Final Office Action for U.S. Appl. No. 17/453,260 dated Oct. 5, 2023. |
| Final Office Action for U.S. Appl. No. 17/653,137 dated Sep. 21, 2023. |
| Final Office Action for U.S. Appl. No. 17/655,464 mailed Sep. 1, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/043818 dated Mar. 24, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/044208 dated May 8, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/049300 dated Jun. 6, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/050909 dated Jul. 24, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/012696 dated Jul. 6, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/051,399 dated Aug. 18, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/446,654 dated Sep. 8, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/646,771 dated Jul. 5, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/657,474 dated Sep. 12, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/661,090 dated Jul. 6, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/663,330 dated Jun. 29, 2023. |
| Non-Final Office Action for U.S. Appl. No. 18/139,523 dated Aug. 17, 2023. |
| Non-Final Office Action for U.S. Appl. No. 18/140,751 dated Sep. 14, 2023. |
| Notice of Allowance for U.S. Appl. No. 16/245,726 dated Jul. 6, 2023. |
| Notice of Allowance for U.S. Appl. No. 17/051,554 dated Jul. 6, 2023. |
| Notice of Allowance for U.S. Appl. No. 17/461,036 dated Jun. 30, 2023. |
| Notice of Allowance for U.S. Appl. No. 17/662,700 dated Jul. 28, 2023. |
| Notice of Allowance for U.S. Appl. No. 18/299,788 dated Jul. 24, 2023. |
| Restriction Requirement for U.S. Appl. No. 17/051,600 dated Sep. 21, 2023. |
| Restriction Requirement for U.S. Appl. No. 17/645,821 dated Jul. 12, 2023. |
| Restriction Requirement for U.S. Appl. No. 17/657,474 dated Jun. 30, 2023. |
| U.S. Appl. No. 15/611,587, filed Jun. 1, 2017. |
| U.S. Appl. No. 15/612,325, filed Jun. 2, 2017. |
| U.S. Appl. No. 18/259,626, filed Jun. 28, 2023. |
| U.S. Appl. No. 18/260,122, filed Jun. 30, 2023. |
| U.S. Appl. No. 18/260,391, filed Jul. 5, 2023. |
| U.S. Appl. No. 18/260,394, filed Jul. 5, 2023. |
| U.S. Appl. No. 18/263,800, filed Aug. 1, 2023. |
| U.S. Appl. No. 18/264,004, filed Aug. 2, 2023. |
| U.S. Appl. No. 18/373,424, filed Sep. 27, 2023. |
| U.S. Appl. No. 18/376,274, filed Oct. 3, 2023. |
| U.S. Appl. No. 18/548,152, filed Aug. 28, 2023. |
| U.S. Appl. No. 18/549,387, filed Sep. 7, 2023. |
| U.S. Appl. No. 18/549,658, filed Sep. 8, 2023. |
| U.S. Appl. No. 18/553,625, filed Oct. 2, 2023. |
| U.S. Appl. No. 63/150,640, filed Feb. 18, 2021. |
| Merriam-Webster Dictionary, , “Embed Definition & Meaning”, https://www.merriam-webster.com/dictionary/embed last accessed Aug. 3, 2023, 2003. |
| Advisory Action for U.S. Appl. No. 16/433,773 dated Dec. 29, 2023. |
| Advisory Action for U.S. Appl. No. 16/904,868 dated Jan. 2, 2024. |
| Advisory Action for U.S. Appl. No. 17/051,585 dated Oct. 17, 2023. |
| Advisory Action for U.S. Appl. No. 17/179,116 dated Jan. 8, 2024. |
| Advisory Action for U.S. Appl. No. 17/446,256 dated Dec. 8, 2023. |
| Advisory Action for U.S. Appl. No. 17/448,811 dated Nov. 15, 2023. |
| Advisory Action for U.S. Appl. No. 17/451,345 dated Oct. 20, 2023. |
| Advisory Action for U.S. Appl. No. 17/453,260 dated Dec. 22, 2023. |
| Advisory Action for U.S. Appl. No. 17/653,137 dated Dec. 1, 2023. |
| Advisory Action for U.S. Appl. No. 17/655,464 dated Dec. 13, 2023. |
| Communication of Notice of Opposition of European Application No. 17807547.9 dated Jan. 5, 2024. |
| Corrected Notice of Allowability for U.S. Appl. No. 16/369,676 dated Dec. 7, 2023. |
| Final Office Action for U.S. Appl. No. 16/433,773 dated Oct. 10, 2023. |
| Final Office Action for U.S. Appl. No. 16/449,039 dated Nov. 21, 2023. |
| Final Office Action for U.S. Appl. No. 16/452,258 dated Dec. 21, 2023. |
| Final Office Action for U.S. Appl. No. 16/904,868 dated Nov. 2, 2023. |
| Final Office Action for U.S. Appl. No. 17/051,399 dated Jan. 8, 2024. |
| Final Office Action for U.S. Appl. No. 17/179,116 dated Oct. 31, 2023. |
| Final Office Action for U.S. Appl. No. 17/450,864 dated Dec. 28, 2023. |
| Final Office Action for U.S. Appl. No. 17/451,354 dated Oct. 30, 2023. |
| Final Office Action for U.S. Appl. No. 17/501,591 dated Nov. 14, 2023. |
| Final Office Action for U.S. Appl. No. 17/646,771 dated Dec. 21, 2023. |
| Final Office Action for U.S. Appl. No. 17/661,090 dated Dec. 11, 2023. |
| Final Office Action for U.S. Appl. No. 17/663,330 dated Dec. 12, 2023. |
| Final Office Action for U.S. Appl. No. 17/664,487 dated Jan. 4, 2024. |
| Final Office Action for U.S. Appl. No. 18/139,523 dated Dec. 22, 2023. |
| Final Office Action for U.S. Appl. No. 18/164,800 dated Dec. 6, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/018474 dated Sep. 11, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/024805 dated Dec. 14, 2023. |
| Issue Notification for U.S. Appl. No. 16/245,726 dated Oct. 18, 2023. |
| Issue Notification for U.S. Appl. No. 17/461,036 dated Oct. 11, 2023. |
| Issue Notification for U.S. Appl. No. 17/663,046 dated Dec. 20, 2023. |
| Non-Final Office Action for U.S. Appl. No. 16/452,145 dated Nov. 2, 2023. |
| Non-Final Office Action for U.S. Appl. No. 16/478,180 dated Nov. 7, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/051,550 dated Oct. 24, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/051,585 dated Jan. 8, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/444,792 dated Nov. 17, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/453,560 dated Oct. 16, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/645,821 dated Oct. 25, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/653,137 dated Jan. 18, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/808,354 dated Nov. 28, 2023. |
| Non-Final Office Action for U.S. Appl. No. 18/140,163 dated Nov. 9, 2023. |
| Non-Final Office Action.for U.S. Appl. No. 18/198,464 dated Dec. 7, 2023. |
| Notice of Allowance for U.S. Appl. No. 16/369,676 dated Nov. 14, 2023. |
| Notice of Allowance for U.S. Appl. No. 17/051,554 dated Oct. 18, 2023. |
| Notice of Allowance for U.S. Appl. No. 17/662,700 dated Nov. 15, 2023. |
| Notice of Allowance for U.S. Appl. No. 18/299,788 dated Nov. 6, 2023. |
| Restriction Requirement for U.S. Appl. No. 18/134,857 dated Oct. 23, 2023. |
| Submission in Opposition Proceedings for European Application No. 17807547.9 filed Jan. 10, 2024. |
| U.S. Appl. No. 17/451,719, filed Oct. 19, 2021. |
| U.S. Appl. No. 18/389,009, filed Nov. 13, 2023. |
| U.S. Appl. No. 18/415,080, filed Jan. 17, 2024. |
| U.S. Appl. No. 18/556,945, filed Oct. 24, 2023. |
| U.S. Appl. No. 18/558,502, filed Nov. 1, 2023. |
| U.S. Appl. No. 18/562,626, filed Nov. 20, 2023. |
| U.S. Appl. No. 18/563,672, filed Nov. 22, 2023. |
| U.S. Appl. No. 18/569,711, filed Dec. 13, 2023. |
| U.S. Appl. No. 18/569,778, filed Dec. 13, 2023. |
| U.S. Appl. No. 63/596,012, filed Nov. 3, 2023. |
| U.S. Appl. No. 63/608,553, filed Dec. 11, 2023. |
| Wikipedia Article, “Zylinder (Geometrie)”, https://de.wikipedia.org/w/index.php?title=Zylinder (Geometrie)&oldid=154862081, version of Jun. 1, 2016, 7 pages. |
| Advisory Action for U.S. Appl. No. 16/449,039 mailed Jan. 25, 2024. |
| Advisory Action for U.S. Appl. No. 17/451,354 mailed Jan. 30, 2024. |
| Advisory Action for U.S. Appl. No. 18/164,800 mailed Feb. 12, 2024. |
| Final Office Action for U.S. Appl. No. 17/446,654 mailed Jan. 31, 2024. |
| Final Office Action for U.S. Appl. No. 18/140,751 mailed Jan. 17, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/051,600 mailed Jan. 17, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/446,256 mailed Feb. 13, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/447,123 mailed Jan. 24, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/448,811 mailed Jan. 17, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/451,345 mailed Jan. 17, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/664,914 mailed Jan. 31, 2024. |
| Non-Final Office Action for U.S. Appl. No. 18/134,857 mailed Jan. 25, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/051,550 mailed Feb. 7, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/453,560 mailed Jan. 31, 2024. |
| Supplemental Notice of Allowance for U.S. Appl. No. 17/051,554 mailed Feb. 14, 2024. |
| U.S. Appl. No. 18/294,370, filed Feb. 1, 2024. |
| U.S. Appl. No. 18/294,403, filed Feb. 1, 2024. |
| U.S. Appl. No. 18/426,795, filed Jan. 30, 2024. |
| U.S. Appl. No. 18/681,987, filed Feb. 7, 2024. |
| U.S. Appl. No. 18/682,006, filed Feb. 7, 2024. |
| Number | Date | Country | |
|---|---|---|---|
| 20210369495 A1 | Dec 2021 | US |
| Number | Date | Country | |
|---|---|---|---|
| 63030685 | May 2020 | US |
